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Abstract 
 
Live Attenuated Influenza Vaccine (LAIV) is used in immunisation 
campaigns but may alter the dynamics of naturally occurring nasal colonisation 
by Streptococcus pneumoniae (Spn), a common human pathogen. We tested 
how the attenuated influenza viruses contained in the vaccine and Spn interact 
in the host’s nasopharynx using for the first time an Experimental Human 
Pneumococcal Challenge model (EHPC) with multiple live pathogens: LAIV and 
Spn of serotype 6B. Two double blinded randomised clinical trials represented 
two scenarios of controlled co-infection: 1) Antecedent LAIV administration 
followed by nasopharyngeal Spn inoculation or 2) Concurrent LAIV administration 
during established Spn colonisation, separated by a 3 day interval. We validated 
non-invasive micro-sampling techniques for mucosal immunity analysis by 
comparing reliability and reproducibility of available methods. Absorptive 
matrices and nasal curettes were established as the preferred techniques to 
investigate lining fluid and immune cells in the nasal mucosa. In addition, we 
collected nasal wash, BAL and serum from healthy adults to investigate immune 
cell recruitment, cytokine and influenza-specific antibody responses using flow 
cytometer, human cytokine 30-plex panel and ELISA analysis. Here, we showed 
that LAIV-induced inflammation in the nasopharynx was associated with Spn 
colonisation. Immune responses to Spn and to the attenuated influenza virus 
were impaired by LAIV, reducing chemoattractant cytokines, recruitment of 
monocytes, and activation of T-cells and neutrophils. In the lung, our results 
demonstrated that LAIV induces inflammatory cytokines produced by T-cells and 
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cytokines against the attenuated influenza virus. In short, LAIV was shown to be 
immunogenic in healthy adults, but less in Spn colonised individuals, highlighting 
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1.1 Streptococcus pneumoniae 
 
Streptococcus pneumoniae (Spn) is a gram-positive cocos of 
approximately 1μm of diameter. This bacteria is a facultative anaerobe, 
generating energy by carbohydrate fermentation. They are generally grouped in 
pairs (diplococci) or in short chains and are able to replicate outside host cells, 
for example in circulation, connective tissues, and tissue spaces such as the 
airway lumen. 
The Spn are coated with a polysaccharide capsule which is its main 
virulence factor 1,2 and protects the bacteria from phagocytosis by host immune 
cells 3,4 as well as reduces the autolysis process 5. Spn capsules vary in size, 
composition, and antiphagocytic properties 6–8 and bacteria presenting different 
types of capsule can colonise hosts simultaneously 9. Moreover, its cytoplasmic 
membrane is composed of lipoprotein bound to lipoteichoic acid by hydrophobic 
interactions. Penicillin-binding proteins represent a small percentage of the 
membrane and are the primary targets of anti-microbials 10. In addition, the 
capsule’s chemical composition is used to categorise the pathogen into 
serotypes, with over 95 serotypes identified 6–8,11–13. Notably, the distribution of 
serotypes varies according to population, geographic region, time of year and 
age of the patient 7.  
Furthermore, many factors contribute to Spn pathogenicity, such as 
pneumolysin, autolysin A, neuroaminidases (NA), choline binding proteins, Spn 
protein C (PspC), Spn surface protein A (PspA) and, especially, pilus subunits 14–
18. Importantly, pneumolysin is a multifunctional toxin that acts as a protective 
antigen 19,20, showing cytotoxic action and activation of the host complement 
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can form biofilms that aid growth during colonisation and contributes to the 
development of invasive diseases 17,22. 
 
1.1.1 Spn colonisation and transmission 
 
Spn is part of the common children’s upper respiratory tract microbiota, 
colonising nostrils, pharynx and larynx 23 for up to 2 weeks, although some 
studies have observed events lasting up to 30 weeks 3,24–28. The nasopharynx is 
the natural site of colonisation 29 and prevalence in healthy individuals varies 
mainly with age, with colonisation rates higher in children than adults and elderly. 
Importantly, Spn colonisation events start soon after birth and prevalence 
increases between 1 and 2 years of age, followed by rate reduction to below 10% 
in adults 27,30–32. In addition, colonisation rates are variable depending on location 
9,33,34. In England, Spn colonisation was observed in 52% of children under 2 
years and 45% in 3 to 4 year old 30, whereas in Gambia and Kenya, the 
prevalence is 80% and 66%, respectively 35,36.  
However, it is important to notice that colonisation rates may vary 
according to sampling techniques and devices used as well as the site and 
frequency of collection in humans. Various methods have been used for 
quantification of Spn colonisation density through nasal lavage such as nasal pool 
devices 37, micro-suction 38, aspiration 39, sponges 40, nasal secretion collectors 
41, gauzes 42 and swabs 43,44. The nasal lavage technique selected in this thesis 
was nasal wash based on the methodology published by Naclerio et al.  45 and 
was previously used successfully in several clinical trials 46–53. This method 
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47, cytological analysis 54 and quantification of inflammatory markers even in 
children 55. 
Nevertheless, regarding increased Spn colonisation rates,  the host can 
show susceptibility characteristics such as sickle cell anaemia, HIV infection, 
neoplasia and chronic degenerative conditions, for instance diabetes mellitus, 
chronic renal failure, nephrotic syndrome, chronic obstructive pulmonary disease 
and chronic liver diseases 56. Additionally, the interaction between Spn and the 
resident microbiota in the upper respiratory tract affect colonisation rates as 
observed in studies with Haemophylus influenzae 57 and Staphylococcus aureus 
17,58,59. Importantly, the continuous use of antibiotics is shown to develop 
resistance in Spn and impact prevalence of bacteria in the population 60,61. 
In healthy individuals, an asymptomatic colonisation triggers immunisation 
9, providing benefits to the host as it develops cellular and adaptive immunity 
49,62. However, even when asymptomatic, colonisation is not entirely benign as it 
primes the host for transmission, tissue invasion or dissemination into the lower 
airways, a prerequisite for invasive disease 58. Notably, the transmission of Spn 
between humans occurs through direct contact or dispersion of aerosol 
secretions by colonised people 27,58,63 with higher rates during the winter season 
64. Moreover, outbreaks of increased Spn transmission can occur in nursing 
homes, day care centres, military units, shelters, schools and prisons 65–71  
 
1.1.2 Pneumococcal epidemiology and disease 
 
Previous to antibiotics development, pneumonia and invasive 
pneumococcal disease were the leading cause of death in humans 19,72 and 
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million people die every year from pneumococcal disease worldwide, with nearly 
all these deaths occurring in children living in low income settings.  
The vast majority of Spn disease are associated with a relatively small 
number of serotypes 74 and requires colonisation of the nasopharynx 58 as well 
as high bacterial load 75,76 and aspiration to the lungs 77 that elicits inflammatory 
pathology in the host 78. Pathogenesis ranges from less severe infections such 
as conjunctivitis, otitis and sinusitis to severe disease such as pneumonia, 
bacteremia and meningitis 79,80. Importantly, invasive pneumococcal disease 
have increased rates in elderly as well as people that present dementia, 
convulsive disorders, heart failure, cerebrovascular disease, chronic lung 
disease, HIV infection, alcoholism, smoking, malnutrition, diabetes, liver cirrhosis, 
renal failure, antibody deficiency and phagocytic function deficiency 81,82. 
 
1.1.3 Immunity to Spn 
 
After Spn entry in the nasopharynx, the host elicits immune responses 
against major infection events, that start with the recognition of bacteria by the 
host immune system which Spn can evade to colonise the nasal mucosa, with 
subsequent invasion into epithelial tissue resulting in damage to the host’s cells 
20,83. Specifically, the innate immune response acts to defend against the bacteria 
by first recognising pathogen-associated molecular patterns (PAMPs) through 
pattern recognition receptors (PRRs) such as the Toll-like receptor (TRL) family 
84,85. In addition, surfactant proteins also play an important role in innate immunity 
phagocytosis of Spn by modulating cellular responses 85,86, activating 
macrophages and neutrophils as well as inducing cytokine production 87,88. In 
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responses and bacteria multiplication without releasing excessive debris in the 
nasopharynx is essential for bacterial clearance and prevention of subsequent 
invasive Spn disease 89,90. 
The innate immune responses against Spn consists of pre-infection 
protective host mechanisms, typically non-specific responses using physical 
(mucus ciliary clearance) and chemical barriers, blood proteins, resident 
phagocytes, neutrophils, macrophages, NK-cells, cytokines and dendritic cells 
(DCs) 91. Indeed, in healthy individuals, asymptomatic colonisation responses 
include classic activation of macrophages, Spn-specific memory CD4+ T-cells, as 
well as sustained TGF-β levels, responsible for increasing T-regulatory cells (T-
regs) in the nasopharynx and protection of the host from exaggerated 
inflammation and tissue damage 49,92–95.  
In addition, this immunising stable colonisation is maintained by a fine 
balance between pro-inflammatory and anti-inflammatory immune responses 96. 
After Spn recognition, monocytes are attracted to the site of the infection and are 
considered one of the essential players in immunity against Spn. Moreover, 
monocytes are white blood cells that typically circulate through the blood for 1 to 
3 days before migrating into other tissues, where they become macrophages or 
DCs 91. Particularly, macrophages are monocytes that have migrated from the 
bloodstream into the tissue where they aid in Spn phagocytosis and cleaning of 
cellular debris 91.  
Activation of macrophages in pneumococcal disease is signalled by TLR - 
a class of PRRs surface receptors expressed by phagocytes and other cell types 
- particularly TLR-2 and TLR-4 97–102 which recognize Spn molecular structures 




28 General Introduction 
enables further host immune responses 106. In mice, the recruitment of monocytes 
correlates with Spn clearance, dependent of TLR-2 and IL-17A 94. Furthermore, 
early recruited monocytes differentiated into macrophages and produce MCP-1 
107. In turn, this cytokine attracts more monocytes to the site. Studies in elderly 
mice have demonstrated that reduced monocyte recruitment to the nasopharynx 
results in decreased bacterial clearance 108. 
Also part of the initial innate immune response are DCs, that play an 
important role in eliciting T-cell responses against Spn later in the infection 91. 
When immature, DCs are located in the respiratory system epithelium and 
migrate to the lymph nodes where they maturate and reside 91. Further, when at 
the infection site, DCs are activated via TLR 109 and decrease Spn-induced 
apoptosis of host’s cells 110,111. In addition, the complement system mediate 
protection from Spn in early infection 112. This mechanism is subverted by the 
bacteria by altering expression of its surface proteins 113. 
Subsequently, if the innate defence is not enough to control the bacteria, 
the adaptive responses armoury of humoral and cellular immunity will mediate 
clearance at the nasal mucosa 89,101. Contrary to initial innate responses, adaptive 
immunity is pathogen specific and elicits memory cells that prevent future 
infections 91. 
Firstly, humoral response develops with the production of antibodies by B-
cells. Notably, induction of antibodies against Spn in human proteins occurs 
naturally throughout the life course as a result of continuous exposure to the 
bacteria, with reported increases in titres of lung and serum antibodies IgA and 
IgG, associated with protection from colonisation 114 and reduced bacteraemia 
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bacterial agglutination and adherence to host cells 117 as well as phagocytosis 
118,119. Spn IgA protease can however be used to evade host IgA defences and 
instead facilitate internalisation of Spn in the epithelium 120.  
Secondly, cellular immune responses have been demonstrated to 
modulate inflammatory responses to Spn, with production of cytokines by 
resident cells. Spn induces production of cytokines TNF-α, IL-6, IL-12, IL-4, IFN-
 and IL-10 121,122. This cytokine cascade then mediate the recruitment of 
neutrophils, monocytes and other effector cells to clear bacteria 78,123 as week as 
differentiate T-cells into T-helper 17 (Th17), T-helper 2 (Th2) and T-regs 124–132.  
Notably, the cytokine TNF- is essential for both innate and adaptive 
responses to Spn, specially for recruitment and activation of neutrophils 133 and 
monocytes 91 to the site of infection. Moreover, IL-4 elicits development of CD4+ 
Th2 cells and IgG signalling 91. whereas IFN- induces activation of T-cells 134, T-
regs 135 and NK-cells 136,137. Importantly, macrophages and DCs produce anti-
inflammatory cytokine IL-10 during pneumococcal disease 3 and is associated 
with host protection against exaggerated pro-inflammation and tissue damage, in 
part because of its ability to inhibit DC activity 138,139.  
In murine models, the bacteria can evade adaptive immunity by inducing 
T-cell death 140. As expected, this mechanism is associated with increases in the 
disease severity 141 and susceptibility to pneumonia 142,143 as Spn colonisation 
control is dependent on CD4+ T-cells 144,145. 
 
1.2 Influenza virus 
 
The influenza virus is an single-stranded, segmented RNA virus, of 
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146. The viral lipidic envelope derives from the host cell’s plasma membrane and 
presents surface glycoproteins hemagglutinin (HA) and neuraminidase (NA) 147 - 
the main targets of immune responses 146 - as well as nucleoprotein molecules 
that protect the RNA strand 148. Both proteins are known to bind to sialic acid 
receptors on the surface of host’s cells, mediating the fusion of the viral envelope 
to the cell membrane 146,149,150. 
Importantly, influenza virus is unique among respiratory virus regarding 
their capability for antigenic variations, as it continuously undergoes mutation to 
escape host immune mechanisms 151. The surface proteins HA and NA can 
mutate in two distinct ways: antigenic drift or antigenic shift. On one hand, 
antigenic drift occurs when there is an accumulation of point mutations due to the 
virus low ability to correct errors after RNA replication 152 and is a common result 
of the pressure exerted by the host immunity 153. On the other hand, antigenic 
shift is the exchange of segments between different influenza virus 154.  
Moreover, the genetic and antigenic differences in virus HAs and NAs are 
commonly used to categorise into types A, B and C 146,153,155. Importantly, 
humans are mostly infected by types A and B, although type C can cause 
subclinical disease 146,156–159. 
 
1.2.1 Influenza epidemiology, transmission and disease 
 
The influenza virus is responsible for an acute infection, also called 
influenza, with global distribution and mostly associated with winter due to 
increased transmission 160,161. The constant contact between humans and the 
various types of influenza virus allows the host to create immunological memory. 
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adapt as well as, less frequently, pandemics 156–158,162. The epidemic and 
pandemic outbreaks of infection results in significant morbidity in all age groups 
163, and mortality in children 164–169, elderly 170,171, as well as in patients with 
chronic and autoimmune diseases 172,173, resulting in over 5 million cases of 
severe illness and approximately half a million deaths annually 174. 
Importantly, since the 16th century, at least 30 pandemic episodes have 
been caused by various mutants and combinations of influenza virus. Noteworthy 
pandemics that occurred in 1918 and 2009 (known as spanish flu and swine flu, 
respectively) were both caused by H1N1 variant of influenza virus, whereas the 
1957, 1968 and 2004 pandemics (known as asian flu, Hong-Kong flu and avian 
flu, respectively) were caused by the H2N2, H3N2 and H5N1 strains 156–158,162,175,176.  
Notably, the spanish flu was known as the deadliest pandemic that ever 
affected humans, infecting 50% of the world’s population and causing 40 to 50 
million related deaths 177. The pandemic occurred in two waves, with the first 
being mild and the second with higher mortality as infection spread even in 
remote areas and islands 178. 
The influenza virus incubation period ranges from 1 to 3 days and recovery 
usually occurs between 4 to 7 days after infection 179. Moreover, transmission 
occurs through direct contact with secretions or aerosols as well as surfaces 
contaminated with the virus 180. In addition, it can remain viable for 8 to 10 hours 
on porous surfaces and for up to 48 hours on non-porous surfaces and hands 181. 
Importantly, transmission is increased under low temperature, high humidity and 
decreased ultraviolet radiation. Furthermore, animal hosts can serve as reservoir 
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Importantly, symptoms include fever accompanied by respiratory and 
systemic symptoms such as nasal obstruction, cough, muscle aches and fatigue 
183,184. In addition, the severity of the influenza infection varies greatly, ranging 
from mild rhinopharyngitis to fatal lung pathology 185.  
 
1.2.2 Immunity to influenza virus 
 
When wild-type influenza virus infects the host, it passes through the 
mucus layer of the upper respiratory tract and is recognised by epithelial cells’ 
pattern recognition receptors TLR2 and Nod2 107,186. In the early stages of 
respiratory infection, T-cells move to the site independent of their specificity 187 
which allows a cascade of adaptive immune responses following virus 
recognition. 
Adaptive immunity elicited against influenza include CD4+ and CD8+ T-cell 
proliferation as well as the production of type I IFNs, IL-6 and MCP-1 186,188 189. 
This inflammatory process recruits neutrophils 189 that limit viral replication in the 
nasopharynx and eliminate infected cells 190. Although influenza virus lung 
infection induces recruitment of monocytes and neutrophils, it decreases their 
ability to phagocytose pathogens as well as the ciliary action of the epithelium 
mucosa 124,191–193.  
Notably, CD8+ T-cells play a critical role in viral clearance through 
production of cytokines that regulate recruitment and function of a broad array of 
cells 194,195. Furthermore, these cells contributes to lysis of influenza-infected cells 
196 by releasing cytolytic granules and producing cytokine IFN- 197–199. 
Interestingly, the absence of CD8+ or IFN--producing CD8+ T-cells were 
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1.2.3 Vaccination against influenza virus 
 
  A World Health Organisation committee meets twice a year to formalize 
the recommendation of influenza virus strains to be included in the vaccine 
composition 201. This committee uses epidemiological data collected throughout 
the year so that the appropriate formulation for the next circulating influenza virus 
is obtained 202,203. Importantly, the benefits of influenza vaccination have been 
extensively proven flu reduction 204–206, with reduction in otitis media incidence 
and use of antibiotics against secondary bacterial infections, as well as school 
absence and transmission 207–209. 
Currently, there are two types of influenza vaccines developed for 
immunisation, containing inactivated or attenuated influenza virus, showed to be 
effective in preventing the development of the disease in multiple placebo-
controlled studies 210,211. Since 1977, the influenza vaccine composition 
recommendation has included three viral strains: 2 type A strains, respectively of 
the H1N1 and H3N2 subtypes, and 1 type B, so the vaccine is considered trivalent. 
Recently, since 2012, licenced vaccines that contain H1N1, H3N2 and 2 type B are 
also used for immunisation and are called tetravalent inactivated influenza 
vaccine (TIV) 212, which is given intramuscularly, and live attenuated influenza 
vaccine (LAIV) 213, which is administered intranasally. 
Inactivated vaccines are produced with the influenza virus inactivated with 
formaldehyde in embryonated chicken eggs 214 and are available in whole, 
fractional and subunit virus forms. On one hand, the whole virus vaccine is 
composed of the whole viral particle, including lipidic cell membrane that is highly 
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components such as HA, NA and nucleoproteins, that are fragmented and then 
purified 216. Moreover, the subunit vaccine consists only of HA and NA, and also 
provides satisfactory protection rates 217. After vaccination with inactivated 
vaccines, the most frequent adverse reactions occur at the application site, such 
as pain and redness in 15% of vaccinated and rarely (in 1 to 2%) fever and 
myalgia is observed 218. 
Similarly, the attenuated vaccine is also produced from the infection of 
influenza virus into embryonic chicken eggs, but in the presence of antibodies 
against the strain’s surface glycoproteins 219–221. However, contrary to the 
inactivated vaccine, production of attenuated influenza virus vaccine takes 
advantage of the segmented nature of the viral genome to recombine genes that 
encode wild-type virus HA and NA as well as 6 internal segments from attenuated 
virus (segments PB1, PB2, PA, M, NP, and NS) 222. Additionally, adverse effects 
from vaccination such as nasal congestion, rhinorrhoea, fever and muscle pain 
223 are uncommon, whereas severe reactions are rare, although it has been 
reported cases of wheezing and post-vaccine hospitalisation 223. 
While both vaccines protect against influenza infection 224, studies have 
shown differences in the immune responses elicited by the inactivated vaccine 
when compared to the live attenuated one. The primary response to inactivated 
vaccine is from B-cells 218,225 that are activated at the immunisation site and 
recruited into the lymph nodes where they proliferate and specialise to migrate to 
other host tissues 226–229. B-cells produce specific antibodies, specially influenza-
specific IgG antibodies in the serum, and lower concentrations of IgM and IgA 
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NA , and can be cross-reactive 232. Further, antibody production elicits memory 
233 and adaptive immunity, especially CD4+ T-cells 234,235. 
On the other hand, with attenuated vaccines, the goal is to induce similar 
immune response to a wild-type influenza infection in the upper respiratory tract, 
inducing local and systemic immunity by viral replication 236, especially influenza 
specific memory T-cells and B-cells 237,238. Notably, only attenuated virus 
stimulates recruitment of CD8 and TCR- T-cells 14,239. In addition, systemic 
immunity is elicited by the attenuated vaccine, however, serum antibodies IgA 
and IgM peak only after 2 weeks post-vaccination whereas IgG takes at least 4 
weeks to reach its maximum levels 240 and titres are not as marked as with 
inactivated vaccines 217 .  
Nevertheless, even with delayed antibody responses, studies have shown 
that the attenuated vaccine formulation present greater persistence 241,242 and 
efficacy against influenza virus in vitro and in children when compared to 
inactivated virus vaccines 210,225,243–247. This suggests that the most appropriate 
way to investigate antibody production against influenza following vaccination is 
by measuring responses in the nasopharynx - the site of infection and replication 
of the wild-type virus 248. Indeed, the attenuated influenza vaccine has been 
shown to induce antibody production in nasal wash, particularly IgA until 6 months 
after vaccination 240, not seen in inactivated vaccines. 
Interestingly, attenuated vaccines have an advantage in those with no 
prior immunity to influenza virus as its efficacy depends on the attenuated virus 
replication in the nose to elicit host immune memory 249. However, inactivated 
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do not elicit immune responses to influenza after vaccination with attenuated virus 
vaccines 250.  
 
1.3 Spn and wild-type influenza virus co-infection 
 
1.3.1 Epidemiology and disease 
 
Secondary infection following pandemic and seasonal influenza virus 
infection is a significant cause of mortality worldwide and, of all influenza co-
infections, Spn is the pathogen most commonly detected 251 - especially during 
influenza pandemics 177,252–255. Spn and wild-type influenza virus co-infection is 
associated with 3 times increased odds of Spn colonisation 46 256 and it causes 1 
in 3 cases of bacterial pneumonia following severe influenza infection 257. In 
addition, higher susceptibility to co-infection has been demonstrated in elderly 
and immunosuppressed, with greater risk of mortality 258 
 
1.3.2 Window of susceptibility to co-infection 
 
A fine balance of pro- and anti-inflammatory responses maintains a stable 
and asymptomatic Spn colonisation 96, however, this equilibrium is altered by 
wild-type influenza virus co-infections, affecting essential inflammatory 
mechanisms in the nasal mucosa 190. The impact on Spn colonisation is due to 
complex interactions between virus, host and bacteria, associated with 
morphologic and immunological alterations of the upper respiratory tract 259. For 
that reason, following host initial recognition and response to virus entry in the 
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generally starts 48 hours after virus infection 186,260,261. Notably, studies have 
demonstrated this modified state can last several months after resolution of 
influenza 262. 
Initially, the virus causes damage to the epithelium, the first line of defence 
against the Spn 196. Viral NAs denude the host epithelial surface by removing 
sialic acid which increases its availability as nutrients for bacteria. The damaged 
epithelium exposes Spn to new receptors in the membrane such as platelet-
activating factor receptor (PAFR) 263,264, increasing bacterial adherence mediated 
by Spn such as PspC 62. Additionally, the virus reduces mucociliary bacterial 
clearance 196 and desensitizes epithelial cells to Spn pathogen-associated 
molecular pattern, impairing bacterial TLRs 193,196,265–267. 
In order to clear the virus, the host elicits production of IFN- mainly by 
CD4+, CD8+ T- and NK-cells, however, this cytokine also modifies macrophages 
in its scavenger receptor, reducing innate defences against Spn by inhibiting its 
phagocytosis 124,186,191,192,262,268. Regarding this aspect, Metzger and Sun 269 
hypothesize that the mechanism of macrophage receptor alteration could have 
evolved to prioritise specific and efficient anti-influenza T-cell memory in acute 
infections. Moreover, reduction in macrophage efficacy consequently diminishes 
the overall production of TNF-α, a strong chemoattractant of neutrophils 188,270.  
In addition, neutrophil influx is also impacted by the increased expression 
of cytokine IL-10, stimulated by rises in IFN-, and type I IFNs levels produced by 
CD8+ T-cells 92,132,186,262,271. Importantly, epidemiological studies in humans show 
that CD8+ T-cell levels were increased by influenza in the lung 188, a critical aspect 
considering the strong correlation between higher levels of IFN--producing CD8+ 
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Furthermore, type I IFNs are responsible for inducing anti-viral cytokines 
and chemokines to stop virus replication and stimulate adaptive immunity. 
However, the exaggerated accumulative production of type I IFNs has been 
related to susceptibility and Spn colonisation, indicated by mice's resistance to 
co-infections in the absence of type I IFN signalling 186,262.  
In short, wild-type influenza virus facilitates adhesion to cells and impairs 
host’s innate and cellular protection, resulting in increased susceptibility to 
colonisation by Spn due to its higher levels in the nasopharynx. Importantly, 
bacterial transmission is increased by influenza infections, and driven by 
increased Spn density 256. 
 
1.3.3 Established Spn and wild-type influenza virus co-infection 
 
Following establishment of Spn and wild-type influenza virus co-infection, 
the presence of high levels of both pathogens in the nasopharynx leads to 
disbalance of inflammatory responses in an attempt to contain invasive virus and 
bacteria 193,196,265,266. In murine models, pneumococcal disease prior to influenza 
virus leads to improved survival, with less morbidity and lung immunopathology 
272. On the other hand, if virus infection occurs before bacterial infection, as first 
shown in a ferret model by McCullers 273, the infection presents increased Spn 
density in the upper respiratory tract 76,92,274. Additionally, there is evidence that 
viral load also increase during co-infection 275 although the unbalanced immune 
responses have no proven correlation to the augmented virus titers 276. 
Importantly, in humans, clearance of co-infection requires a robust adaptive 
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Firstly, the host’s nasopharynx reacts to co-infection with Spn-induced 
TGF-β and T-reg levels increase 92. Importantly, exaggerated production of this 
cytokine during co-infection suppresses NK-cells induction and macrophages 
activation 132 and is associated with decrease in IL-2 concentration which, in turn, 
impairs T-cell development 188 and reduces levels of CD3+ and CD4+ T-cells 270. 
Further, the established co-infection express signals to the host from both 
pathogens, causing reducing of TCR- and Th17 T-cells levels 270.  
In addition, modulation of B-cell response is altered by inhibition of cell 
development and activation 188,270,277. The reduced B-cell immunity is possibly 
due to the decreased numbers of CD4+ T-cells, which reduces support of B-cell 
function and production of cytokines 270. Interestingly, murine models 
demonstrate that the decrease in influenza-specific T-cell response correlates 
with the increase in T-regs 188 due to T-reg production of adenosine, perforin and 
granzymes that are toxic to T-cells 278. Moreover, similarly to influenza virus 
infection alone, low levels of CD8+ T-cells are associated with virus and Spn co-
infection severity 188,199. Importantly, in murine models of coinfection, CD8+ T-
cells are presented in lower levels 188, consequently reducing production of 
cytokines such as TNF- 188 and recruitment of immune cells 188.  
Interestingly, studies have shown contradictory results regarding how 
excess production of type I IFN affects Spn and wild-type-influenza co-infection. 
Although there are studies where type I IFNs do not affect neutrophil recruitment 
186, the majority of researches demonstrate impairment in both neutrophils 
192,279,280 and macrophages due to lower expression of keratinocyte 
chemoattractant (KC) and MCP-1, of critical role in control of co-infection 186. 
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suppresses expression of pro-inflammatory cytokine IL-17 - especially by TCR-
 - associated with increased Spn density 262 due to its involvement in the early 
control of bacteria by recruiting neutrophils to the infection site.  
In summary, Spn and wild-type influenza virus co-infection deregulates 
innate and adaptive immune defences and increases Spn colonisation rates and 
density which, in turn, increases Spn transmission 273, susceptibility to invasive 
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1.4 Murine Spn and live attenuated influenza virus (LAIV) co-
infection 
 
A controversial epidemiological aspect of Spn and wild-type influenza virus 
co-infection is the use of live attenuated influenza virus to immunize the mucosa 
due to its mimicry of virus natural infection in the nasopharynx and activation of 
host inflammatory immune responses. Importantly, this transitory attenuated 
virus replication, known as viral shedding, increases Spn levels analogously to 
wild-type influenza virus infection and affects Spn-induced immunity as well as 
colonisation density, transmission and host susceptibility to invasive disease 281. 
Similarly to Spn and wild-type influenza co-infection models, when mice 
were primarily colonised with Spn, LAIV is efficient in controlling infection and 
reducing mortality 76. Additionally, in models where mice are first vaccinated, it 
has been shown an inflammatory state 274 presenting increased type I IFN levels 
274, bacterial density and duration of Spn colonisation 282 as well as bacteria 
transmigration to the middle ear 274 283. On the other hand, LAIV was not shown 
to increase Spn density in the lower respiratory tract 274 as the vaccine consists 
of temperature sensitive virus strains that replicates only in the upper airways. 
Interestingly, human models of co-infection with Spn and LAIV is also associated 
with increased Spn density 284 and disease. However, opposite to mice models, 
some studies indicate that LAIV in humans is protective against acute otitis media 
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1.5 Experimental Human Pneumococcal Challenge model for 
study of Spn and attenuated influenza virus co-infection 
 
The Experimental Human Pneumococcal Colonisation (EHPC) 47 is an 
unique model of controlled infection that induces nasal Spn colonisation in 
healthy adults at a typical density and duration (1 to 3 weeks) in 50% of subjects 
following inoculation with different strains of Spn 47. This model is the ideal 
biological system to study immune protection mechanisms as the onset, duration 
and termination of a colonisation episode are known and serial measurements 
of immune responses can be made with controlled rates of Spn acquisition and 
density. 
In healthy adults, EHPC was used to determine that Spn challenge 
confers protection against recolonisation and development of invasive disease 
by inducing immunoglobulin production in the nasal mucosa 62 and blood 49 as 
well as pulmonary IL-17A+ CD4+ memory T-cells 287. Furthermore, in the nasal 
mucosa, protection granted by EHPC is associated with pre-existing antibodies 
against PspA but not with antibodies against capsular polysaccharide 288. In 
addition, establishment and maintenance of Spn colonisation after EHPC was 
associated with TGF-β1 and T regulatory cells 92. 
The EHPC model has also been used as a new method for vaccine testing 
51,52 and investigation of nasal microbiota and its interaction with Spn. Past 
studies have demonstrated that viral infections increase susceptibility to EHPC, 
eliciting higher levels of mucosal factor H and Spn density. This occurs due to 
higher Spn adherence caused by increased epithelial layer inflammation and 
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colonisation of the nasopharynx using EHPC and different strains inoculated 
were demonstrated to cause disturbances in microorganism diversity 289.  
1.6 Thesis Aims 
 
Our main goals and specific aims for this thesis were to:  
 
1. Determine the best methodology for investigation of immune responses in 
the nasopharynx by: 
a. Comparing phenotypes of cells collected by nasal curettage and 
nasal wash. 
b. Analysing cytokine levels using nasosorption and nasal wash. 
 
2. Investigating if Spn colonisation, LAIV and TIV alter cell-mediated 
response in the nasal mucosa of human hosts by: 
a. Assessing recruitment of monocytes, neutrophils, T-cells and DCs. 
b. Measuring activation levels of neutrophils and T-cells. 
 
3. Assess if Spn colonisation, LAIV and TIV alter cytokine responses in the 
nasal mucosa of human hosts by: 
a. Analysing induction of cytokines related to pro- and anti-
inflammatory responses. 
b. Investigating levels of elicited cytokines that regulate cell growth 
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4. Determine the effects of Spn colonisation, LAIV and TIV on immunity 
against influenza antigens by: 
a. Establishing levels of induced T-cell subsets producing cytokines 
after stimulation with influenza, including CD4+, CD8+, T-regs, TCR-
 and TRM T-cells. 
b. Comparing antibody levels to influenza (IgA and IgG) in serum, 
nasal wash and lung. 
 
 














46 Materials and methods 
2.1 Funding and study approvals 
 
Funding for Antecedent LAIV as well as Concurrent LAIV studies were 
received by the Bill and Melinda Gates Foundation, the UK Medical Research 
Council, the Liverpool School of Tropical Medicine, the Royal Liverpool, 
Broadgreen University Hospitals NHS Trust (United Kingdom) and Coordenação 
de Aperfeiçoamento de Pessoal de Nível Superior (Brazil). 
Ethical approvals are shown in Table 2 and were obtained from the 
National Health Service Research Ethics Committees (REC), and Royal 
Liverpool and Broadgreen University Hospitals Trust. The clinical trial 
authorisation was granted by the Medicines and Healthcare products Regulatory 
Agency (MHRA). Volunteer appointments took place in the Clinical Research Unit 
at the Royal Liverpool University Hospital. 
 









47 Materials and methods 
2.2 Recruitment and ethics/ consent 
 
The recruitment for the Antecedent LAIV study cohort took place in the 
period between October 2015 and April 2016 while the Concurrent LAIV study 
cohort was recruited between October 2016 and April 2017. Volunteers gave 
written and informed consent and recruited if they were healthy, non-smokers 
and aged 18-50.  
 
Subjects were unable to participate if they fell under any of the following 
exclusion criteria during screen:  
• Influenza or Spn vaccination or clinically confirmed disease in the 
preceding 2 years; 
• Close contact with “high-risk” individuals (children under 5, 
immunosuppressed or elderly); 
• Current febrile illness; 
• Use of antibiotics; 
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2.3 Study design 
 
In both the Antecedent LAIV and Concurrent LAIV studies subjects were 
randomised using a permuted-block algorithm (1:1 in blocks of 10) held in sealed 
envelopes and distributed in two groups based on vaccination status: TIV 
(Control) or LAIV. 
Volunteers participating in the Antecedent LAIV study were vaccinated at 
day -3 and inoculated at day 0 relative to Spn inoculation serotype 6B (Figure 1). 
On the other hand, subjects in the Concurrent LAIV study were inoculated with 
Spn at day 0 and vaccinated at day +3 post-inoculation. Vaccinations were done 
in the TIV control group with TIV flu jab (2015/2016 Fluarix Tetra, 
GlaxoSmithKline, UK) and the LAIV group with LAIV nasal spray (Fluenz Tetra 
and FluMist Tetra, AstraZeneca, UK). 
In the Antecedent LAIV study, 222 participants consented, 162 were 
screened, 137 vaccinated (n=68 with LAIV, n=69 with TIV) and 130 were 
inoculated. Volunteers were excluded from analysis based on screen failure 
(n=5), stopping follow-up appointments (n=7), vaccination error (n=8), natural 
colonisation by Spn at baseline (n=1) and use of antibiotics (n=1). In addition, 
demographics were similar between groups (Table 4). 
Furthermore, in the Concurrent LAIV study, 316 participants consented, of 
which 206 were screened, 198 were inoculated and 194 were vaccinated (n=97 
with LAIV, n=97 with TIV). Volunteers were excluded from analysis based on 
screen failure (n=8), stopping follow-up appointments (n=4), vaccination error 
(n=13), naturally colonisation by Spn at baseline (n=13) and naturally acquired 
Spn colonisation during the study (n=4). Moreover, demographics were also 
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Figure 1. Design for Antecedent LAIV and Concurrent LAIV studies. The diagram represents 
nasopharyngeal inoculation with Spn serotype 6B as a red dotted line, and vaccination as a dotted 
purple line. In the Antecedent LAIV study, participants were screened on day -4, vaccinated on 
day -3, inoculated on day 0, and samples were collected on days +2, +7, +9, +29 and +30 relative 
to inoculation. In the Concurrent LAIV study, participants were screened at day -5, inoculated at 
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Table 3. Demographics of volunteers enrolled in the Antecedent LAIV and Concurrent LAIV 
studies. 
Antecedent LAIV 
 LAIV TIV Overall 
Median age (range) 20.0 (18.0 - 34.0) 20.0 (18.0 - 48.0) 20.0 (18.0 - 48.0) 
Female (%) 65.5 51.6 58.1 
Median dose (range) – 
CFU/nostril 
74,500 (51,000 - 
88,000) 
77,250 (51,000 - 
88,000) 
76,333 (51,000 - 
88,000) 
Time from vaccination to 
inoculation – days±SD 
3.0 ± 0.1 3.0 ± 0.1 3.0 ± 0.1 
Concurrent LAIV 
 LAIV TIV Overall 
Median age (range) 20.0 (17.0 - 46.0) 20.0 (18.0 - 32.0) 20.0 (17.0 - 46.0) 
Female (%) 53.4 56.7 55.2 
Median dose (range) - 
CFU/nostril 
82,167 (60,667 - 
93,000) 
81,083 (60,667 - 
93,000) 
82,167 (60,667 - 
93,000) 
Time from vaccination to 
inoculation – days ± SD 
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2.4 Study schedules 
  
During the studies, volunteers were sampled for nasal wash (NW), nasal 
cells, nasosorption (NS), serum and bronchoalveolar lavage (BAL) in specific 
timepoints after screening (Table 5 and 6). All sampling, processing and analysis 
were made while blinded to vaccination group and colonisation status, assuring 
unbiased analysis. 
 
Table 4. Visit schedule for sample collections in the Antecedent LAIV study. 
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2.5 Clinical procedures 
  




LAIV (Fluenz Tetra and FluMist Tetra, 
AstraZeneca, UK); TIV (2015/2016 Fluarix Tetra, 
GlaxoSmithKline, UK) 
Nasal cells collection 




Nasosorption strip (Nasosorption™, Hunt 
Developments) 
BAL collection 
Benzodiazapine antagonist (flumazenil)  
Benzodiazepine (midazolam)  
Sphygmomanometer Instilagel (lidocaine gel)  
2% and 4% lidocaine (Xylocaine)  
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2.5.2 Volunteers symptoms log and evaluation of procedures 
 
Volunteers from the Antecedent study (n=148) documented local and 
general symptoms for a period of 7 days since baseline (day -4). Severity ratings 
ranged from 1 (less severe) to 7 (more severe). Symptoms evaluated were 
sneezing, runny or itchy nose, congestion, throat symptoms, cough, eye or ear 
symptoms, headache, as well as additional symptoms added by the participants. 
For evaluation of the tolerance to the sample collection procedures, 
volunteers were asked to use a 5-point modified Likert scale. A range of 1 to 5 
was used to collect individual opinions about how painful and how uncomfortable 
the procedure was, along with if it made their eyes water. 
 
2.5.3 Experimental Human Pneumococcal Carriage (EHPC) 
model 
 
Volunteers (n=130 in Antecedent and n=198 in Concurrent study) received 
100µl of Spn inoculum prepared in advance (see section 2.6.3) inside each nostril 
and remained seated for up to 15 minutes without blowing their nose or sniffing 
up. Each subject received an emergency pack including: Amoxicillin 9x500mg, 
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2.5.4 Vaccination 
 
Participants were vaccinated (n=137 in Antecedent and n=194 in 
Concurrent study) with either nasal LAIV (Fluenz Tetra or FluMist Tetra, 
AstraZeneca, UK, used interchangeably due to acquisition shortages) paired with 
intramuscular placebo (0.5 mL of normal saline) or with intramuscular TIV 
(2015/2016 Fluarix Tetra, GlaxoSmithKline, UK) paired with nasal placebo (0.2 
mL normal saline) as control. In the Antecedent study, 65 volunteers received 
LAIV and 64, TIV, whereas in the Concurrent study 97 subjects were vaccinated 
with LAIV and 97 with TIV. 
 
2.5.5 Nasal wash collection 
 
The NW method used in the thesis was previously described by Gritzfeld 
et al. 47 and based on the methodology published by Naclerio et al. 45. For 
collection of NW, participants received 5 mL of saline in one nostril, rapidly 
expelling the liquid for collection in a foil bowl 45. This procedure was repeated 
until 20 mL was used in one nostril. The liquid collected was stored at room 
temperature for further processing described in Section 2.6.5. Importantly, NW 
was performed after nasosorption but before nasal curettage in order to keep 
samples uncontaminated. 
 
2.5.6 Nasal cells collection 
 
The nasal inferior turbinates were visualised with a light with the participant 
being seated with the head tilted posteriorly. A curette (ASL Rhino-Pro©, 
Arlington Scientific) was used to scrape a small collection of cells from the nasal 
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placed on ice containing PBS+Ca+Mg (Section 2.5.1) for processing, described 
in Section 2.6.6. Importantly, nasal scrape was performed before NW and 
nasosorption since the intervention could contaminate other collected samples. 
For this procedure to be done consistently, all clinical staff responsible for 
nasal cell collection was trained using 3D models of human noses as well as 
volunteers. The results of collected epithelial, immune, neutrophils, T-cells and 
monocytes were compared between the clinical staff. In addition, quality checks 
of the results were performed continuously throughout the studies and additional 
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2.5.7 Nasosorption collection 
 
The nasosorption collection technique used in this thesis was based on 
the methodology previously published by Thwaites et al. 290. An adsorptive matrix 
strip (Nasosorption™, Hunt Developments) was held parallel to the volunteers’ 
nasal septum with the absorptive part inside one of the nostrils for nasal fluid 
collection. The nostril was pressed so that the strip held its place for 2 minutes. 
After that, the strip was deposited in its original tube and froze immediately in a -
80oC freezer for further analysis. Importantly, nasosorption was the first sample 
collected from the nose of volunteers, before NW and nasal curettage, in order to 
preserve the nasal lining from contamination. 
 
2.5.8 Serum collection 
 
Serum was sampled from volunteers by collecting 5 mL of blood and 
storing in a tube with anticoagulant EDTA. Immediately after collection, the 
sample was placed in a -80oC freezer for future experiments. 
 
2.5.9 Bronchoalveolar lavage collection 
 
The collection of BAL cells was conducted at the clinical research unit 
(CRU) of the Royal Liverpool Hospital. To assure safety during the procedure, 
monitoring equipment was available (three lead ECG, pulse oximeter, 
spygnomanometer and anaesthetic support, Section 2.5.1). 
First, oxygen was delivered via nasal cannula at up to 4L/min and topical 
anaesthesia with lidocaine was achieved in the nasal passages (using Instilagel) 
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was completed using 4% lidocaine, further mucosal anaesthesia was achieved 
by using 2 mL aliquots of 2% lignocaine.  
Following, the bronchoscope was inserted in the nostril and positioned. 
Further, hand suction was performed using 50 mL saline syringe and repeated 3 
times, using a maximum volume of 200mL. The sample was kept in ice and the 
bronchoscope was slowly withdrawn and processed as described in Section 
2.6.8. For an additional following of volunteers’ health, participants were followed-
up at 1-5 days post-procedure with a clinical examination. 
  
2.5.10 Safety monitoring 
 
 Every volunteer that enrolled in the studies was required to send a text 
message to the clinical team every day for a week. If the text was not received, 
the volunteer was contacted personally to ensure their safety.  
Antibiotics were used if the volunteer was colonised with Spn at the end of 
the study or in the event they were unwell. In case of serious disease, a direct 
admission to the Infectious Disease ward at the Royal Liverpool University 
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2.6 Laboratory procedures 
 





- Blood agar plates PB0122A (Oxoid, Basingstoke, UK) 
- Vegitone media (Oxoid, Basingstoke, UK) 
- Glycerol 
- PBS (Thermo Fisher Scientific, Waltham, MA) 
- 6 and 12-well plates (Thermo Fisher Scientific, Waltham, MA) 




- Blood agar plates PB0122A (Oxoid, Basingstoke, UK) 
- 96-well Nunc Maxisorp plates (Thermo Fisher Scientific, Waltham, MA) 
Nasal cells 
staining 
- 70 µm filter (Thermo Fisher Scientific, Waltham, MA) 
- Cytometer (LSRII, BD Bioscience, UK) 
 
- Antibodies for Concurrent LAIV study: Epcam-PE; HLADR-PE.Cy7; 
CD66b-FITC (Biolegend, San Diego, CA); CD3-APC.Cy7; CD14-
Percp.Cy5.5 (BD Biosciences, San Jose, California, USA); CD45-
PACOrange (Thermo Fisher Scientific, Waltham, MA). 
 
- Antibodies for Antecedent LAIV study: Epcam-PE; HLADR-PE.Cy7; 
CD16-APC; CD66b-FITC, CD19-BC650, CD8-BV785 (Biolegend, San 
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Jose, California, USA); CD45-PACOrange (Thermo Fisher Scientific, 
Waltham, MA). 
 
- Anti-Rat Ig, κ/Negative Control Compensation Particles Set (BD 
Biosciences, San Jose, CA). 
- Anti-Mouse Ig, κ/Negative Control Compensation Particles Set (BD 
Biosciences, San Jose, CA). 
Luminex human 
cytokine 30-plex 
- Human cytokine magnetic 30-plex panel (Thermo Fisher Scientific, 
Waltham, MA) 
- Hu Cytokine Mag 30-plex antibody bead solution (Thermo Fisher 
Scientific, Waltham, MA) 
- Hu Cytokine Mag 30-plex Biotinylated Ab (Thermo Fisher Scientific, 
Waltham, MA) 
- Hu 14-Plex standard (Thermo Fisher Scientific, Waltham, MA) 
- Hu 16-Plex standard (Thermo Fisher Scientific, Waltham, MA) 
- Wash Solution Concentrate (Thermo Fisher Scientific, Waltham, MA) 
- Incubation buffer (Thermo Fisher Scientific, Waltham, MA) 
- Biotin Diluent (Thermo Fisher Scientific, Waltham, MA) 
- Streptavidin RPE diluent (Thermo Fisher Scientific, Waltham, MA) 
- Streptavidin RPE concentrate (Thermo Fisher Scientific, Waltham, MA) 
- Assay diluent (Thermo Fisher Scientific, Waltham, MA) 
- Luminex MAGPIX calibration/verification kits. Calibration Kit MPX-CAL-
K25 and Performance Verification Kit MPX-PVER-K25 (Thermo Fisher 
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- Luminex MAGPIX + xPonent software for Luminex (Thermo Fisher 
Scientific, Waltham, MA) 
- 96-well Nunc Maxisorp plates (Thermo Fisher Scientific, Waltham, MA) 
- Magnetic 96-well plate separator (Thermo Fisher Scientific, Waltham, 
MA) 
- Luminex Flat bottom 96-plate and black cover (Thermo Fisher Scientific, 
Waltham, MA) 
BAL processing 
- 6-, 12-, 24-, 48- and 96-well plates (Thermo Fisher Scientific, 
Waltham, MA) 
- Complete medium: RPMI, 10% of heat-inactivated fetal bovine serum 
(FBS, Thermo Fisher Scientific, Waltham, MA), PSN antibiotic mixture 
(Penicillin-Streptomycin-Neomycin). 
- FBS-DMSO: 90% heat-inactivated fetal bovine serum (FBS) and 10% 
Dimethyl sulfoxide (DMSO), (Thermo Fisher Scientific, Waltham, MA) 
BAL intracellular 
staining 
- PBS (Thermo Fisher Scientific, Waltham, MA) 
- Cytometer (LSRII, BD Bioscience, UK and Becton Dickinson, UK) 
- TIV (2015/2016 Fluarix Tetra, GlaxoSmithKline, UK) 
 
- Antibodies: CD3-APCH7 (clone SK7), TCR-–PECy7 (clone 11F2), IL-
10–BV786 (clone JES3-9D7), IL-17A–BV510 (clone N49-653), (BD 
Biosciences, San Jose, California, USA), CD4–PerCP5.5 (clone SK3), 
CD8–AF700 (clone SK1), CD69–BV650 (clone FNSO), CD25-
PE.TxsRed (clone M-A251), CD103–BV605 (clone Ber-ACT8), CD49a-
APC (clone TS2/7), FOXP3-FITC (clone 259D), IFN--PE (clone 
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- Anti-Rat Ig, κ/Negative Control Compensation Particles Set (BD 
Biosciences, San Jose, CA). 
- Anti-Mouse Ig, κ/Negative Control Compensation Particles Set (BD 
Biosciences, San Jose, CA). 
- ArC Amine Reactive Compensation Bead Kit (Invitrogen Corporation, 
Carlsbad, CA). 
IgG and IgA 
ELISA 
- 96-well Nunc Maxisorp plates (Thermo Fisher Scientific, Waltham, MA) 
- TIV (2015/2016 Fluarix Tetra, GlaxoSmithKline, UK) 
- PBS (Sigma Aldrich, Gillingham, UK) with 0.005% Tween 20 (Sigma, 
PP1379, Deisenhofen, Germany) 
- 1% bovine serum albumin (BSA) in PBS 
- 0.1% bovine serum albumin (BSA) in PBS 
- Detection antibodies: anti-human-IgG (Sigma, A3188, Deisenhofen, 
Germany) and anti-human-IgA (Sigma, I1261, Deisenhofen, Germany) 
- Streptavidin−Alkaline Phosphatase (Bio-rad, STAR6B, Hercules, CA) 
- p-Nitrophenyl Phosphate (Sigma-Aldrich, Poole, U.K.) 
- FLUOstar Omega ELISA microplate reader (BMG Labtech) 
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2.6.2 Reagent preparations 
 
2.6.2.1 For Experimental Human Spn Inoculation 
 
Reagent Consumables and procedures 
STGG medium291 
Consumables:  
- Oxoid tryptone-soya broth (CM 129) 3.0mL 
- glucose 0.5g 
- Oxoid skim milk powder (CM L31) 2.0g 
- glycerol 10.0mL; double distilled water 100.00mL.  
Procedure: 1 mL amounts were dispensed into bijoux’s and autoclaved 
at 15lb for no more than 10 min. The tubes were stored at 4-6°C. 
 
2.6.2.2 For nasal wash processing 
 
Reagent Consumables and procedures 
STGG medium291 
Consumables:  
- Oxoid tryptone-soya broth (CM 129) 3.0mL 
- glucose 0.5g 
- Oxoid skim milk powder (CM L31) 2.0g 
- glycerol 10.0mL; double distilled water 100.00mL.  
Procedure: 1 mL amounts were dispensed into bijoux’s and autoclaved 
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2.6.2.3 For nasal cells processing and staining 
 
Reagent Consumables and procedures 
PBS+Ca+Mg 
Consumables:  
- phosphate-buffered saline (PBS, Thermo Fisher Scientific, Waltham, 
MA) 
- heat-inactivated fetal bovine serum (FBS, Thermo Fisher Scientific, 
Waltham, MA) 
- ethylenediaminetetraacetic acid (EDTA, Thermo Fisher Scientific, 
Waltham, MA) 
Procedure: Phosphate-buffered saline (PBS) + 0.5% heat-inactivated 
fetal bovine serum (FBS) and 2.5 mM ethylenediaminetetraacetic acid 
(EDTA) 
Violet viability dye 
working solution 
Consumables:  
- LIVE/DEAD Fixable Dead Cell Stain kit (Invitrogen, UK) 
- PBS+Ca+Mg 






64 Materials and methods 
2.6.2.4 For Luminex human cytokine 30-plex 
 
Reagent Consumables and procedures 
Wash buffer 
Consumables: Wash Solution Concentrate (Thermo Fisher Scientific, 
Waltham, MA) 




Consumables: Biotin Diluent and Biotinylated Antibody (Thermo Fisher 
Scientific, Waltham, MA) 
Procedure: 25µL of Biotin Diluent and 2.5µL of 10x Biotinylated Antibody 
per well 
Substrate mix 
Consumables: RPE-Diluent and Streptavidin-RPE (Thermo Fisher 
Scientific, Waltham, MA) 
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2.6.2.5 For staining of non-adherent cells from BAL tissue 
 
Reagent Consumables and procedures 
Complete Medium 
- RPMI (Thermo Fisher Scientific, Waltham, MA) 
- FBS (10%, heat inactivated, Thermo Fisher Scientific, Waltham, 
MA) 
- PSN antibiotic mixture (Penicillin-Streptomycin-Neomycin) 
TIV for stimulation TIV (2015/2016 Fluarix Tetra, GlaxoSmithKline, UK) 
Violet Viability dye 
working solution 
Consumables:  
- Violet Viability dye (LIVE/DEAD Fixable Dead Cell Stain kit, 
Invitrogen, UK) 
- PBS (Thermo Fisher Scientific, Waltham, MA) 
Procedure: 1µL of Live/Dead diluted in 300µL PBS 
BD Golgiplug BD Golgiplug (BD Biosciences, San Jose, California, USA) 
Fix/Perm working 
solution 
Consumables: Foxp3/Transcription Factor Staining Buffer Set 
(eBioscience, 00-5523) 




Consumables: Foxp3/Transcription Factor Staining Buffer Set 
(eBioscience, 00-5523) 
Procedure: 90µL of 10x Permeabilisation buffer (Foxp3/Transcription 
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2.6.3 Bacterial stock preparation 
 
For the preparation of the bacterial stock used in the Experimental Human 
Spn Inoculation, first a “parent” stock was prepared, quantified, aliquoted and 
frozen for future use. To assure no animal products besides Spn was inoculated 
into volunteers, the stock was grown in Vegitone Infusion broth (Oxoid, 
Basingstoke, UK) as well as all processing involving the bacteria was performed 
with sterile fumehood, incubator and pippetes. 
The first stock was prepared by streaking Spn of serotype 6B in a blood 
agar plate (Oxoid, Basingstoke, UK), which was incubated overnight at 37°C and 
5% CO2. After that, each half of the plate was swabbed and mixed separately 
with 12 mL of Vegitone. The cell cultures were incubated in plates (Thermo Fisher 
Scientific, Waltham, MA) at 37°C until detection of turbidity in the liquid was 
achieved or at least for a period of 2 hours. 
Subsequently, 40 mL of Vegitone was added to each culture, the OD was 
quantified in a Spectrophotometer and adjusted to 0.15 OD at 620nm using the 
Bacterial stock quantification method (see section 2.6.3.1) for further incubation. 
During incubation at 37°C and 5% CO2, the culture’s OD were measured hourly 
until an OD between 0.30-0.35 - early-mid log phase - was achieved. In one 
culture, 10% sterile glycerol was added, and 1 mL aliquots were prepared and 
frozen in a -80°C freezer while the other culture was centrifuged at 3345xg for 15 
minutes. Afterwards, the supernatant was removed, and the pellet was 
resuspended with 22.5 mL of Vegitone. 
Aliquots of 1 mL were prepared and stored at -80°C. Later, 10% sterile 
glycerol was added to the culture and after at least 48 hours, three aliquots were 
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2.6.3.1 Bacterial stock quantification 
 
To determine the CFU/mL in the final aliquots of bacterial stock, we diluted 
it by adding 20µL of stock to 180µL of sterile saline. After that, a dilution of 1:10 
was prepared in a 96-well plate (Thermo Fisher Scientific, Waltham, MA) and 
three 10µL drop of the 6 first dilutions were added to a blood agar plate divided 
in 6 parts (Figure 2). The plate was left to dry and then incubated for 9 to 16 hours 
at 37°C and 5% CO2. 
 
Figure 2. Agar blood plate layout for quantification. Division of agar blood plate into 6 sections 
represented by black lines and three 10µL drops of diluted bacterial stock per session represented by blue 
drops. 
 
In the next day, the visible colonies in each plate division were counted by 
dividing the number of colonies by three, taking the average number, multiplying 
by the dilution factor and further dividing by the volume of 10mL. Finally, the 
number was multiplied by 1000 to obtain a result in CFU/mL as described in the 
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2.6.4 Experimental Human Spn Inoculation 
 
 For the inoculation of volunteers, after quantification of stable and accurate 
CFU results from the bacterial stock, an aliquot was thawed from the -80oC 
freezer and centrifuged at 17000xg for 3 minutes. The supernatant was removed, 
the pellet was resuspended with 1 mL of saline and centrifuged again with the 
same specifications. One more time, the supernatant was removed, and 1 mL of 
saline was added to the sample. 
Using the original concentration of stock, the aliquots were diluted 1:10 
according to the desired dose of 80,000CFU/100μl by using the Bacterial stock 
quantification procedure (see section 2.6.3.1). 
 
2.6.5 Nasal Wash Processing 
 
Following NW collection (see section 2.5.4), the sample obtained from the 
volunteer was immediately centrifuged at 3345xg for 10 min at room temperature. 
Aliquots of 1 mL were taken from the supernatant and stored in a -80oC freezer 
for further analysis. 
 After that, the pellet was resuspended with 100µL of STGG and quantified 
for investigation of respiratory pathogens, using the Bacterial stock quantification 
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2.6.6 Nasal cells processing 
 
Upon collection of nasal cells described in Section 2.5.5, the sample was 
dislodged from the rhinoprobes by washing the cells with PBS+Ca+Mg (Section 
2.6.2.3). Subsequently, the cells were centrifuged at 440xg for 5min at 4oC and 
the supernatant was removed so the cells could be stained (see section 2.6.6.1). 
 
2.6.6.1 Nasal cells staining 
 
After processing, the nasal cells from volunteers were resuspended in 
50µL of Violet viability dye working solution (Section 2.6.2.3) and incubated for 
15 minutes in ice. Afterwards, the antibody mixture was added accordingly 
(Section 2.6.6.1.1) and incubated for 15 minutes in ice. 
 Then, the stained cells were washed with 3.5 mL of PBS+Ca+Mg (Section 
2.6.2.3) at 440g for 5mins and 4oC, resuspended, filtered over a pre-wetted 70µm 
filter and placed into a tube for further cytometry analysis. The contents were 
centrifuged again and resuspended in 200µL of PBS+Ca+Mg in the Antecedent 
LAIV and of cell fix (BD Biosciences) in the Concurrent LAIV study for acquisition 
on a flow cytometer (LSRII, BD Bioscience, UK and Becton Dickinson, UK). 
 
2.6.6.1.1 Antibodies for nasal cell staining 
 
In order to investigate cells populations in the human nasopharynx and 
cell-mediated immune responses to LAIV and Spn colonisation, nasal cells were 
stained for monocytes, neutrophils, lymphocytes and cell activation markers.  
During the Antecedent LAIV study (Table 6), cells were dyed with the 
extracellular antibodies CD45 (for identification of neutrophils and immune cells), 
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epithelial cells), CD14 (to distinct monocytes), CD3 (for recognition of T-cell 
population), CD16 and CD66b (for measurement of neutrophil recruitment) as 
well as the marker HLA-DR was analysed, an MHC class II cell surface receptor 
expressed by human leukocytes and commonly used to identify an activation 
signal 292,293. 
Likewise, in the Concurrent LAIV study (Table 6), volunteers’ cells were 
stained with CD45, Epcam, CD14, CD19, CD3, CD66b and HLADR, with 
additional BDCA-1, BDCA-2, CD4 and CD8, markers for a deeper 
immunophenotyping of subsets of dendritic and T-cells present in the sample. 
The results were analysed using FlowJo X (Treestar Oregon, USA) and the gating 
strategy is shown in Figures 3 and 4 for the Antecedent and Concurrent LAIV 
studies, respectively. Samples with less than 500 immune cells (15% of all 
samples measured) or 250 epithelial cells were excluded from further analysis. 
Flow cytometry compensation was set individually for each of the 
fluorochromes in the panel in order to adjust for spillover (physical overlap) 
between fluorochrome channels and acquire trustworthy results. Two sets of 
single-stained compensation samples were prepared using Anti-mouse and anti-
rat BD positive and BD negative compensation beads accordingly (Biosciences, 
San Jose, CA, Section 2.6.1). Compensation staining for the Violet fluorescent 
dye was performed separately using the ArC Amine Reactive Compensation 
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 Table 6. Surface antibody markers applied to nasal cells in each study as well as volume used 





Concurrent LAIV study 
Antibody 













Antecedent LAIV study 
Antibody 
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Figure 3. Representative flow plots of nasal ells from the Antecedent LAIV study analysis by flow cytometry. The gating tree was set as follows. 
A: FSC-A/FSC/SSC-A (represents the distribution of cells in the light scatter based on size and intracellular composition, respectively) to B: FSC-H/FSC-
A (to distinct single cells) to C: Viability/Epcam (Live gate represents the fraction of viable cells within the sample analysed and Epcam was used for 
identification of epithelial cells) to D: AlexaFluor/CD45 positive (represents the immune cells) to E: SSC-A/CD66b (identifies non-neutrophils and 
neutrophils) to F: CD66b/CD16 (from the analysed neutrophils, CD66bHi were gated) or G: CD3/CD14 (from the analysed aneutrophils, T-cells, monocytes 
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Figure 4. Representative flow plots of nasal T-cells from the Concurrent LAIV study analysed by flow cytometry. The gating tree was set as 
follows. A: FSC-A/FSC/SSC-A (represents the distribution of cells in the light scatter based on size and intracellular composition, respectively) to B: FSC-
H/FSC-A (to distinct single cells) to C: Viability/Epcam (Live gate represents the fraction of viable cells within the sample analysed and Epcam was used 
for identification of epithelial cells) to D: AlexaFluor/CD45 positive (represents the immune cells) to E: SSC-A/CD66b (identifies non-neutrophils and 
neutrophils) to F: SSC-A/CD66b (from the analysed neutrophils, CD66bHi were gated) or G: SSC-A/CD14 (from the analysed non-neutrophils, T-cells, 
monocytes and other cells populations were identified) to H: HLA-DR/CD19 (identifies B-cells) to I: CD8/CD3 (from non-B-cells, identifies NK cells, CD8+ 
T-cells and CD8- T-cells). 
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2.6.7 Luminex Human Cytokine 30-plex of nasal fluid 
 
Nasal fluid was collected, processed and frozen from a set of volunteers 
(see section 2.5.6). After thawing, the nasosorption strip (NS) was washed with 
100µL of Assay Diluent (Thermo Fisher Scientific, Waltham, MA. Section 2.6.1) 
and centrifuged for 10 min at 16000xg in order to elute the sample. Subsequently, 
30µL of the liquid was placed on a plate followed by addition of 30µL of Assay 
diluent and 30µL of incubation buffer to each well.  
Afterwards, 75µl of the mixture was transferred to the Luminex plate. 
Furthermore, 60µL of standard was combined with 30µL of incubation buffer and 
75µL of this solution was also moved to the Luminex plate (all Thermo Fisher 
Scientific, Section 2.6.1). At this time, 12.50μL of Antibody Bead was added into 
the wells of the Luminex plate filled with samples or standards. The duplicate 
samples were acquired by transferring 43.75µl from a well to the well beside it. 
The plate was incubated overnight at 4oC under agitation on an orbital shaker 
(500 rpm agitation). 
On the next day, the plate was washed twice with 200μL Wash Solution 
and 25μL Biotinylated Detector Antibody was added to each well (Thermo Fisher 
Scientific). Following incubation for 1 hour, the plate was washed twice one more 
time and 25μL Streptavidin-RPE solution was added to each assay well (Thermo 
Fisher Scientific). The samples were incubated for 30 minutes at room 
temperature on an orbital plate shaker. 
Moreover, the wells were washed three times and 105μL 1X Wash 
Solution to each assay well and placed on an orbital plate shaker for 2–3 minutes 
prior to analysis. The plate was then acquired using a 30-plex magnetic human 
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LX200 with xPonent 3.1 software following manufacturer’s instructions. Cytokines 
with a CV>50% for a given sample were excluded from further analysis. 
 
2.6.8 BAL Processing 
 
2.6.8.1 Isolation of non-adherent cells from BAL tissue 
 
The BAL sample collected from a set of volunteers (see Section 2.5.8) was 
passed through a sterile medical cotton gauze into 50 mL Falcon tubes in ice in 
order to remove viscous portions of the lavage. Next, 10 mL of sample from the 
filtered sample was separated and centrifuged at 400xg for 10min at 4oC. Its 
supernatant was removed, and the pellet resuspended with 2 to 3 mL of complete 
medium (Section 2.6.1). After that, the centrifugation process was carried on 
again and the pellet was resuspended in FBS-DMSO (Section 2.6.1) to obtain a 
concentration of 2x105 cells/mL Finally, the BAL cells were stored in a -80oC 
freezer overnight then transferred to liquid nitrogen for storage and further 
analysis. 
 In order to isolate BAL lymphocytes for antibody staining, on the next day, 
the aliquot was resuspended and washed with 1 mL of complete medium at a 
time until clean. The sample was topped up with media to complete 50 mL and 
centrifuged at 400xg for 10 minutes in 4oC. The pellet was then reconstituted with 
complete medium and plated (Thermo Fisher Scientific) to obtain a final 
concentration of 5x105 macrophages per well. Following, the plates were 
incubated at 37°C for 2 to 3 hours to promote adherence of macrophages. Finally, 
the non-adherent cells were removed from the plate supernatant after rinsing and 
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2.6.8.2 Intracellular staining of non-adherent cells from BAL 
tissue 
 
Non-adherent BAL cells obtained from volunteers (see section 2.6.8.1) 
were counted and incubated at 1x106 cells/mL in complete medium at 37oC. 
Samples were stimulated with influenza antigens (TIV) concentrated at 1.2g/mL 
(see Section 2.6.2.5) or left unstimulated as negative control and incubated for 2 
hours. Then, 1000x diluted BD Golgiplug (see Section 2.6.2.5) was added and 
cells were incubated for an additional 16 hours as previously described. 
After 16 hours, the cells were washed with 3 mL of PBS, resuspended and 
stained with Violet Viability dye working solution (see Section 2.6.2.5). After 15 
minutes, cells were stained with the surface markers CD3-APCH7 (clone SK7), 
TCR-–PECy7 (clone 11F2) from BD Biosciences (San Jose, California, USA), 
CD4–PerCP5.5 (clone SK3), CD8–AF700 (clone SK1), CD69–BV650 (clone 
FNSO), CD25-PE.TxsRed (clone M-A251), CD103–BV605 (clone Ber-ACT8), 
CD49a-APC (clone TS2/7) from Biolegend (San Diego, CA) according to Table 7 
and incubated for 15 minutes. Cells were fixed and permeabilised using the 
Foxp3/Transcription Factor Staining Buffer Set as per manufacturer’s instructions 
described in Section 2.6.2.5. Cells were stained with intracellular markers 
FOXP3-FITC (clone 259D), IFN--PE (clone 4S.B3), TNF-α–BV711 
(cloneMAb11) Biolegend (San Diego, CA) and IL-10–BV786 (clone JES3-9D7) 
IL-17A–BV510 (clone N49-653) from BD Biosciences (San Jose, California, 
USA). (Table 7). For investigation of TRM T-cell responses to influenza, we used 
the extracellular markers CD69, CD103 and CD49a. In this thesis, TRM was 
ultimately defined as CD4+ CD69+ cells, following scientific consensus 294, as over 
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markers CD103 and CD49a. In addition, to assess the frequency of regulatory T-
cells (T-regs) in the lung, we measured the frequency of CD25hi FOXP3+ T-regs 
among CD4+ T-cells using intracellular staining. 
After 30 minutes, samples were washed with 3 mL of PBS and 
resuspended in 200µL of PBS for acquisition on a BD LSR flow cytometer (Becton 
Dickinson, UK). Flow cytometry data was analysed using FlowJo cell analysis 
software version 10 (FlowJo, LLC, Ashland, Ore) and the gating strategy as 
shown on Figure 5 and 6. For participants displaying less than 500 immune cells 
for a given sample, the participant was excluded from further analysis. Similarly, 
to staining nasal cells, flow cytometry compensation was done individually for 





78 Materials and Methods 
 
Table 7 Surface antibody markers applied to BAL cells as well as volume used for each sample. 
Extracellular staining 
Antibody Volume (µL) 
CD49a-APC 3 
CD69 – BV650 3 
CD3-APCH7 3 
TCR- – PECy7 3 
CD25-PE.TxsRed 2 
CD103 – BV605 1.5 
CD4 – PerCP5.5 0.5 
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Figure 5. Representative flow plots of BAL T-cells and cytokine production analysed by flow 
cytometry using intracellular staining. To assess the frequency of cells in human BAL, we employed the 
following gating strategy. (A) FSC-A/SSC-A to (B) FSC-H/FSC-A (in order to exclude doublets) to (C) 
CD3/Viability to (D) CD4/TCR-γδ to (E) SSC-A/CD8. (F) The markers CD25/FOXP3 (CD25hi and FOXP3+) 
were used to assess the frequency of T-regulatory cells in human BAL after restimulation with influenza 
antigens. A negative control (CD25- and FOXP3-) was used to validate flow cytometric data. To assess 
cellular production of (G) IFN-, (H) IL-17A, (I) TNF-α, cells were stained by intracellular staining after 
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Figure 6. Representative plots of TRM T-cells identified by flow cytometry. The markers 
CD69, CD103 and CD49a were used to assess the frequency of TRM cells in human BAL. (A) 
CD4+ T-cells gated into CD69 negative and positive cells. CD103 and CD49 marker expression 
are shown for (B) CD4+ CD69+ T-cells and (C) CD4+ CD69- T-cells. (D) CD8+ T-cells gated into 
CD69 negative and positive cells. CD103 and CD49 marker expression are shown for (E) CD8+ 
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2.6.9 ELISA procedures 
 
2.6.9.1 IgG and IgA ELISA on serum, nasal wash and BAL 
 
ELISA was used to quantify levels of IgG and IgA antibodies to influenza 
in the serum, nasal wash and BAL supernatant from volunteers participating in 
the Antecedent LAIV study. Pooled sera of 7 TIV vaccinated volunteers was heat-
inactivated (at 56oC for 30 min) and used as standard in both total IgA and IgG 
to influenza ELISA. Antibody levels were expressed in arbitrary units. For IgG 
standard preparation, a dilution of 1:4000 was applied, while for IgA was diluted 
1:40.  
Briefly, 96-well plates (Thermo Fisher Scientific) were coated with 100µL 
of 0.2 µg/mL TIV in PBS overnight at room temperature. During the experiment, 
each wash consists of washing plates three time with PBS with 0.005% Tween 
(Sigma, see Section 2.6.1). After incubation overnight, plates were washed 
following blocking with 100µL of PBS with 1% BSA for 1 hour in room 
temperature. Then, plates were washed, and samples were added in duplicate 
and incubated for 2 hours at room temperature.  
For detection of IgG and IgA, a 1:5000 and 1:4000 dilution of anti-human-
IgG and anti-human-IgA antibodies respectively(Sigma, see Section 2.6.1), was 
made using 0.1% BSA and 100µL added to each well after washing and 
incubated at room temperature for 2 hours. For IgA ELISA, 100µL of 1:2000 
dilution of Streptavidin−Alkaline Phosphatase using 0.1% BSA was added to 
each well and incubated at room temperature for 1 hour. 
Then, for both IgA and IgG to influenza, plates were washed and 100µL of 
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at room temperature for a fixed period (IgA: 30 min and IgG: 90 minutes). The 
optical density of each well was measured at 405nm using a FLUOstar Omega 
ELISA microplate reader, the average blank corrected value was calculated for 
each sample and the data analysed using Omega Analysis. 
 
2.7 Statistical analysis 
 
All sampling, processing and analysis were performed while blinded to 
vaccination and colonisation group to achieve unbiased results. Non-parametric 
tests were used for statistical analysis since number of samples were insufficient 
for a normal distribution of results. Statistics were calculated in GraphPad prism 
version 5.0, 6.0 and 7.0 for Windows (GraphPad Software, California USA) and 
R Statistical Software (R Foundation for Statistical Computing) with packages 
gplots, shiny, mass, vegan and RcolorBrewer. Differences were considered 
statistically significant if p≤0.05. Benjamini-Hochberg multiple correction was 
performed in R for 30-plex cytokine data. 
 



















The human oro/nasopharynx is the major site of Spn colonisation 295 and 
LAIV attenuated virus replication 153,296. In order to establish reliable and 
reproducible methodologies for nasal cell immunophenotyping and cytokine 
analysis of the mucosal immune responses, we assessed and compared 3 
minimally-invasive micro-sampling techniques (nasal wash, nasal curettage and 
nasosorption). 
Currently, the most used method for collecting cells from within the 
nasopharynx is a NW procedure. The technique is well tolerated, however, 
luminal cell populations can vary significantly from intra-mucosal populations 
297,298. Cell collection using nasal curettes is an alternative method that has 
previously been used to collect epithelial cells for culture, as well as for gene 
expression analysis 299,300. Herein, we sampled the nasal mucosa using nasal 
curettes and studied the composition of nasal cells using flow cytometry. Nasal 
immune cell yields and viability were compared between nasal curettes and nasal 
washes. 
Cytokines and other soluble immune mediators are also commonly 
measured in NW samples. However, an absorptive matrix to collect nasal fluid 
(NS) has been tested in neonates, and has the potential to be better tolerated 
and more widely applicable 301. This technique has recently been used to 
investigate nasal responses to grass pollen, LPS and rhinovirus 302–304.  
Immunological findings in murine, or other animal models, often fail to 
translate to humans, which indicate the need for more accurate non-invasive 
techniques to measure immunological response in the nose. Furthermore, an 
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understanding of the cellular components in the human nasopharynx. In this 









3.2.1 Volunteers recruitment 
In total 240 samples were collected from 139 healthy individuals 
(requirements described in Section 2.2) from the Antecedent Study (Section 2.3) 
to investigate techniques for studying immune responses at the mucosal level. 
 
3.2.2 Collection of nasal samples 
All participants were sampled for NW (Section 2.5.4) using 20 mL of sterile 
saline and underwent nasal curettage and NS collection. 
In order to collect nasal cells by curettage, volunteers had their inferior 
turbinates scraped using a rhinoprobe (BRAND ASL Rhino-Pro©, Arlington 
Scientific) in each nostril, as described in Section 2.5.5. The sample was placed 
in 8 mL of PBS +Ca+Mg and placed on ice for further analysis. 
For NS collection, an adsorptive matrix strip (Nasosorption™, Hunt 
Developments) was inserted into the nostril and placed against the nasal lining 
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3.2.3 Flow cytometry analysis 
As described in Section 2.6.6.1, cells were dislodged from the curette and, 
were spun down (440xg for 5 minutes) and resuspended in PBS+Ca+Mg 
containing LIVE/DEAD Fixable Aqua Dead Cell Stain (ThermoFisher). After 15 
minutes incubation on ice, a cocktail of conjugated antibodies against key cell 
surface markers such as Epcam-PE, HLADR-PECy7, CD16-APC, CD66b-FITC 
(Biolegend), CD3-APCCy7, CD14-PercpCy5.5 (BD Biosciences) and CD45-
PACOrange (ThermoFisher) was added to the cells. Following a further 15 
minutes incubation on ice, cells were filtered over a 70μm filter (ThermoFisher). 
Next, the cells were spun down (440xg for 5 minutes), resuspended in 
PBS+Ca+Mg and acquired on a flow cytometer (LSRII, BD). NWs were similarly 
processed excluding the dislodging step as described in Section 2.6.5. Flow 
cytometry data were analysed using Flowjo V.10 (Treestar). 
 
3.2.4 Cytokine detection  
As described in Section 2.6.7, nasal lining fluid was extracted from 
nasosorption strips by centrifugation (1880xg for 10 minutes) and frozen at -80oC 
until use. Supernatant from NW was collected by centrifugation at 1008xg for 3 
minutes and was stored at -80oC until use. The human magnetic 30-plex cytokine 
kit (ThermoFisher) was used to detect 30 cytokines simultaneously on a LX200 
with xPonent3.1 software (Luminex) following manufacturer’s instructions 
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3.2.5 Scoring tolerability of nasal sampling procedures 
Following NS, nasal curettage and NW, participants rated using a 5-point 
modified Likert scale (Section 2.5.2) how ‘painful’ and how ‘uncomfortable’ each 
procedure was, and how much it made their ‘eyes water’. 39 participants also 
completed a symptoms log for 7 days documenting both local and general 
symptoms with severity ratings from 1 to 7 (Section 2.5.2). 
 
3.2.6 Multi-dimensional scaling and heat map generation  
Multi-dimensional scaling and heat map representations were generated 
using statistical software R. Flow cytometry data (epithelial cell yield, 
immunophenotyping and activation) was log-transformed and a distance-matrix 
was calculated. The Kruskal stress was calculated using the ‘MASS’ package on 
the R software. Heat maps of log-transformed cytokine data were generated 
using the ‘gplots’ package. 
 
3.2.7 Statistical analysis  
As described in Section 2.7, non-parametric two-tailed tests were used 
throughout using Prism 5 (Graphpad). If 2 groups were compared, a Mann-
Whitney test was used. If multiple groups were compared, a Kruskal-Wallis test 
was used, followed by a Dunn’s post-test. A Spearman test was used to measure 
correlations between 2 continuous variables. Analysis of similarity (ANOSIM) 











Nasal curettage yields robust and reproducible data 
To verify the repeatability of nasal curettage, we initially collected samples 
from the left and right nostril of 3 healthy volunteers and performed flow cytometry 
to identify cellular composition (Figure 7). 
Samples from both nostrils were processed independently and 
frequencies of neutrophils, monocytes and T-cells were compared for each of the 
3 volunteers. Cellular samples collected from the 2 nostrils were similar for each 
of the 3 volunteers, compared to samples collected from the other 2 volunteers. 
These results demonstrate the repeatability of nasal curettage as well as the 









Figure 7. Repeatability of nasal curettage sampling. Nasal cells were collected from the left (L) 
and right (R) nostril of three volunteers, processed independently and their composition was 
assessed by flow cytometry. After excluding debris and doublets, epithelial cells were identified by 
Epcam expression. A viability dye and CD45 were used to identify live immune cells. Among those 
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To verify that nasal curette sampling yields stable data, cells were 
collected from healthy volunteers (n=117) over a 5-month period (Figure 8). The 
percentage of neutrophils and T-cells among immune cells was stable during this 
period (Figure 8A). Moreover, for a subset of volunteers, up to 4 nasal samples 
were collected during a 33 day period. The levels of both neutrophils and T-cells 
correlated on an intra-individual level between repeated sampling (Figure 8B and 
8C). These results demonstrate that despite variation between individuals, the 
immunological profile in the nose is stable in the absence of disease or immune 
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Figure 8. Nasal curettage yields reproducible and consistent results over time. (A) The percentage of 
neutrophils (red) and T-cells (blue) in 218 nasal cell samples collected over a 5-month period (n=117 volunteers, 
sampled up to 5 times). Circles represent individual samples and loess curves are depicted for both populations. (B, 
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Nasal curettage and nasal wash yield different cell populations 
We then compared the yield and composition of nasal cells collected using 
curettes to those collected using a NW (Figure 9A and 9B). Nasal curettage 
yielded a median of 4367 (interquartile range, IQR: 1511–10348) immune cells 
and 1407 (IQR: 570–3194) epithelial cells, respectively. The number of immune 
cells obtained was similar between NW and nasal curette. In contrast, there were 
a median 22.7-fold increased numbers of epithelial cells collected by nasal 
curette (Figure 9A, p<0.05). Figure 9B shows the composition of the collected 
immune cells. NW immune cells consisted almost exclusively of neutrophils 
(median 96%, IQR: 93–97%). On the other hand, nasal curette samples 
contained predominantly neutrophils (median 64%, IQR: 39–79%, p<0.0001 
compared to NW), but also consisted of a larger fraction of T-cells than NW 
(median 16%, IQR: 9–38%, p<0.0001 when compared to NW).  
A median of 2591 (IQR: 691–7666) neutrophils and 633 (IQR: 210–1740) 
T-cells were acquired per sample. Nasal curette samples also contained more 
HLA-DR+ cells, which are likely to consist of B-cells and DCs (median 1.7%, IQR 
0.9–3.2%, p<0.001 compared to NW). Of all immune cells collected by curettage 
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Figure 9. Comparison of samples collected by nasal wash and nasal curette. (A) Immune 
(black) and epithelial (grey) cell yields were compared between nasal wash pellets and nasal 
curette samples. Individuals samples and median with interquartile range are shown. (B) Median 
levels of neutrophils (blue), T-cells (red), monocytes (black) and lineage- HLA-DR+ (grey) among 
immune cells in nasal curette (n=139 individuals) and nasal wash (n=8) samples. **p<0.01, 
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Cytokine detection from nasal lining fluid using nasosorption 
devices  
To investigate cytokines in the nose, we used NW and NS to collect nasal 
lining fluid. The median volume of nasal lining fluid returned using this technique 
was 42.5μL (IQR: 29.25–71.25μL, n=41). We compared cytokine levels in nasal 
lining fluid and NW supernatant for 30 cytokines by Luminex (Figure 10A).  
Levels of different cytokines varied considerably, with median levels of IL-
1RA at 212,000pg/mL and GM-CSF at 2pg/mL in nasal lining fluid. Relative 
cytokine abundancy correlated well between NS and NW, as cytokines that were 
abundant in NS were also highly present in NW. Of interest, T-cell cytokines (IL-
10, IL-17, IFN-, TNF-α, IL-4, IL-5, IL-2) were only present at low levels (Figure 
10B), which correlates with the absence of T-cells in the lumen. Growth factors 
as EGF, HGF and VEGF were expressed at moderately high levels, reflecting the 
homeostatic nature of mucosal surfaces. 
Levels of cytokines were higher in NS compared to NW (median 4.7x, IQR: 
3.1–8.0x). However, some cytokines had a ratio between NS and NW that 
differed substantially from this: IL-1RA and IL-5 were respectively 51.5x and 
45.2x higher in NS than in NW. In contrast, MIG, RANTES and IP-10 were found 
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Figure 10. Comparison of cytokine levels in samples collected by NW and using NS strips. (A) A heat 
map depicts log-transformed cytokine concentrations, with yellow and blue indicating low and high levels, 
respectively. Each of the columns corresponds to 1 sample (n=6 NW and NS) and each of the rows to 1 
cytokine. A distance tree shows similarity between cytokines. (B) The ratio of cytokine concentrations 
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Methods of nasal micro-sampling are well tolerated by 
volunteers and do not lead to symptoms 
Using the 5-point modified Likert scale, 20 participants gave ratings for 
nasal curettage (88 ratings) and NS (60 ratings) with regards to pain, discomfort 
and lacrimation (Table 2).  
For nasal curettage and NS (Figure 11), the proportion of responses that 
reported any degree of pain (any score > 1) were 73% and 10%, respectively. 
Additionally, the proportion of responses that reported any degree of discomfort 
(score > 1) were 86% and 47%, respectively. Moreover, the proportion of 
responses that reported any degree of lacrimation (score > 1) were, 84% and 
28%, respectively.  
For NS the maximum rating was moderate for levels of discomfort, pain or 
causing lacrimation. A small proportion of responses rated nasal curettage as 
very painful (2%), uncomfortable (8%) or causing lacrimation (6%). 
Finally, we assessed whether these sampling methods led to increased 
general and nasal symptoms over a longer period in 39 healthy volunteers (Table 
3). All participants had NW procedures and 20 of those participants had nasal 
curettage and NS to investigate whether these additional sampling methods 
affect nasal symptoms. Daily symptom logs for nasal and general symptoms were 
completed by all volunteers. Age and sex distribution were similar in each group. 
The median ratings for overall nasal symptoms were 1 (range 1–4) and 1 (range 
1–5) in the group with and without additional nasal sampling, respectively.  
In the symptoms log, a score of 1 represented ‘none to occasional 
symptoms’ and 5 represented ‘moderately bothersome’. Comparison of area 
under the curve between the 2 groups showed no significant difference in either 
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and general symptoms between participants with and without additional nasal 
sampling on day 1 (before additional sampling) and day 3 (after additional 
sampling). There were no significant differences between nasal or general 
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Table 8. Levels of pain, discomfort and lacrimation associated with nasal curettage and NS. 
Volunteer responses (%, n) 
PAIN RATING 
Pain rating Nasal curettage Nasosorption 
1 - Not at all  27% (24) 90% (54) 
2 – Slightly 43% (38) 10% (6) 
3 – Moderately 27% (24) 0% (0) 
4 – Very 3% (2) 0% (0) 
5 – Extremely 0% (0) 0% (0) 
DISCOMFORT RATING 
Discomfort rating Nasal curettage Nasosorption 
1 - Not at all  13% (12) 53% (32) 
2 – Slightly 47% (42) 40% (24) 
3 – Moderately 32% (28) 7% (4) 
4 – Very 8% (7) 0% (0) 
5 – Extremely 0% (0) 0% (0) 
LACRIMATION RATING 
Lacrimation rating Nasal curettage Nasosorption 
1 - Not at all  17% (14) 71% (4) 
2 – Slightly 60% (53) 22% (13) 
3 – Moderately 18% (16) 7% (4) 
4 – Very 3% (3) 0% (0) 












Figure 11.Tolerability of novel nasal sampling methods. The percentage of volunteers rating (A) nasal 








Here we described 2 novel non-invasive nasal mucosal micro-sampling 
techniques and their use for measuring immunological parameters in the nasal 
mucosa: 1) using nasal curettes to collect cells from the inferior turbinate and; 2) 
absorptive matrices to collect nasal lining fluid (NS). Both techniques were well 
tolerated and yielded reproducible and robust data. We demonstrated differences 
in immune populations and activation state in nasal mucosa compared to 
nasopharyngeal lumen in healthy adults. We also found superior cytokine 
detection with NS compared to NW. This was the first time that nasal cells 
collected in this way were analysed by flow cytometry, demonstrating the 
presence of immune cells in these samples. 
NW yielded almost exclusively neutrophils, indicating differences in 
immune cells were collected by NW and nasal curette. The lack of T-cells in NWs 
reflects earlier findings showing that neutrophils and monocytes readily enter the 
lumen in the gut, while T-cells are mostly associated with the sub-epithelial layer 
47,305,306. 
We also assessed the use of NS devices to collect nasal lining fluid. 
Importantly, the nasal lining fluid contained cytokines in concentrations that were 
increased compared to concentrated NW. Moreover, a positive correlation 
between cytokine levels that were detected in both nasal lining fluid and those 
from NW was observed. However, the ratio between cytokine concentrations in 
nasal lining fluid and NW was not similar for all cytokines assessed, which could 
be due to the existence of cytokines in different nasopharyngeal compartments. 
As NWs sample the entire nasopharynx in contrast to a localised sample coming 
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Alternatively, these differences could arise from cytokines binding affinities to the 
NS paper. NW is currently the most commonly used method to obtain samples 
from the nasopharynx, however, it has limited application in multiple clinical 
scenarios such as sampling of children as NW consists of holding in and expelling 
saline through the nose. Here we have demonstrated that NS has greater 
sensitivity than the traditional NW and is extremely well tolerated by participants. 
Nevertheless, there are potential issues with sample collection using NS devices, 
such as poor return volume, which was corrected in future samplings by adding 
diluent buffer to the samples afterwards. 
In conclusion, non-invasive mucosal sampling yields nasal cells and nasal 
lining fluid that can be used to study both cellular and soluble immune responses 
at the mucosal surface. Such samplings are well-tolerated and do not lead to a 
change in nasal symptoms being ideal for research. These techniques were used 
throughout the 2 LAIV studies and can be widely implemented in order to provide 
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4.1 Introduction 
 
The mucosal tissue is described to have an epithelial cell layer that 
interacts directly with the environment, making it the body's first line of defence 
against infectious agents. Mucosal surfaces have a high tolerance to antigens 
that are not dangerous, coming from ingested food or commensal 
microorganisms, inhibiting unnecessary local and systemic immune responses in 
order to maintain homeostasis and normal physiological functions 307. 
The mucosa form the largest mammalian lymphoid organ system. As part 
of this complex barrier, the nasal mucosae are protected by specialised innate 
and adaptive immune mechanisms can recruit a large number of immune cells 
such as monocytes, neutrophils, DCs and T-cells, which can be resident cells or 
migratory cells that travel through the mucosa-associated lymphoid tissue 
(MALT) 308,309. 
Nasopharyngeal Spn colonisation is the primary reservoir for bacterial 
transmission 310 and a prerequisite of invasive disease 311. However, it is common 
for humans to be naturally colonised by Spn asymptomatically many times during 
lifetime for weeks or even months at a time 312. Therefore, a successful control of 
the Spn load by immune cells in the nasal mucosa is the key for preventing severe 
illness 313 as uncontrolled Spn colonisation and increased bacterial load has been 
associated with transmission within households 310, elevated risk of Spn 
pneumonia 266 and mortality 314.  
Moreover, it is known that during Spn and wild-type influenza virus co-
infection, the host ability to control bacterial growth is affected 75,270,315–317. The 
presence of the virus induces additional adaptive CD8+ T-cell responses in the 
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Consequently, adaptive and innate responses synergize to culminate in an 
inflammatory cytokine and chemokine storm 271. 
It is important to notice that influenza attenuated viruses contained in the 
LAIV can impact on Spn density in children 318. Furthermore, LAIV in 2 to 4 year 
old increased prevalence of Spn when compared to other microbiota in the nose 
318. In adults, asymptomatic viral infection has been shown to predispose to 
experimental colonisation by facilitating Spn adherence to the epithelium 46. 
Murine models also confirms that LAIV increases susceptibility to and duration of 
Spn colonisation with similar mechanisms to the wild-type influenza virus 282. 
However, as most of the observed interactions between Spn, attenuated 
influenza virus and host derive from mice and children models, these findings 
may not accurately correspond to the human adult counterpart. Therefore, it 
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4.2 Methods 
 
4.2.1 Volunteer recruitment, vaccination and inoculation 
216 healthy adult volunteers were recruited to the Antecedent and 
Concurrent LAIV study (Section 2.2) and received vaccination (LAIV or TIV as 
control) and intranasal inoculation with Spn6B (EHPC). In the Antecedent study, 
vaccine was administered 3 days before inoculation, while in the Concurrent 
study, subjects received the vaccine 3 days after the inoculation (Section 2.3). 
 
4.2.2 Nasal cells collection, processing and staining 
Before and after vaccination and inoculation, 106 volunteers recruited to 
the Antecedent study and 110 to the Concurrent study had their inferior turbinates 
scraped with a rhinoprobe (Section 2.5.5) on predetermined timepoints. 
Nasal cells were washed (Section 2.6.6) and stained with extracellular 
antibodies (Section 2.6.6.1). In the Antecedent study, nasal cells were stained 
with against CD45, Epcam, CD14, CD3, CD16, CD66b and HLADR cell surface 
markers , whereas in the Concurrent study 2 additional antibodies for DCs (anti-
BDCA-1 and anti-BDCA-2) were included in the flow cytometry panel. 
Volunteers were stratified into 4 groups for analysis: TIV Spn-, vaccinated 
with TIV and negative for Spn colonisation (Antecedent n=25, Concurrent n=33); 
TIV Spn+, vaccinated with TIV and Spn colonised (Antecedent n=18, Concurrent 
n=25); LAIV Spn-, vaccinated with LAIV and not colonised (Antecedent n=26, 
Concurrent n=30); LAIV Spn+, vaccinated with LAIV and Spn colonised 
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4.2.3 Flow cytometry and statistical analysis 
To account for the differences in the length of sample collected by 
curettage and accurately compare the number of immune cells recruited to the 
nasal mucosa, the analysis of specific cell numbers was made using the number 
of the specific cell population compared to the epithelial cell numbers contained 
in the collected sample. The recruitment of immune cells was analysed in each 
group by comparing the median number of immune cells to epithelial cell ratio at 
each timepoint compared to baseline (Antecedent study: day -4; Concurrent 
study: day -5 from Spn inoculation) by Wilcoxon test. Comparisons of median 
results between groups were done by Mann-Whitney test.  
Stained nasal cells were analysed in a flow cytometer using FlowJo X 
(Treestar) and gating strategy is shown in Section 2.7. Statistical analysis was 
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4.3 Results 
 
4.3.1 Antecedent LAIV 
In the Antecedent study, 106 volunteers were vaccinated with either TIV 
(n=51) or LAIV (n=55) and inoculated with Spn 3 days later. Subjects were 
sampled for nasal cells on days -4 (baseline), +2, +7, +9, +29 relative to Spn 
inoculation. For analysis, volunteers were stratified into the groups: TIV Spn-, TIV 
Spn+, LAIV Spn- and LAIV Spn+. In addition, for analysis regarding only Spn 
colonisation status, volunteers were divided into the groups: Spn- (not Spn 
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Induction of monocyte recruitment to the nose by Spn colonisation 
is impaired by antecedent LAIV vaccination 
 
Here we compared the recruitment of monocytes to the nasopharynx using 
the median of monocytes to epithelial cell ratio. When assessing all volunteers 
colonised by Spn independent of vaccine, Spn-induced monocyte recruitment 
was significant at day +2 (Spn- vs. Spn+, median 2.1-fold increase, p=0.014, 
Figure 12B). Importantly, when stratified by vaccination, colonised volunteers 
showed a significant induction in recruitment at day +2 when compared to 
baseline, but only when vaccinated with TIV (TIV Spn+: median 2.3-fold increase, 
p=0.038). Further, at day +9, a median 3.4-fold increase in monocyte levels was 
still observed in TIV Spn+ (p=0.002). The significant induction shown in this group 
continued to be demonstrated as far as day +29, with 3.1-fold increase (p=0.030, 
Figure 12A). However, in colonised subjects, LAIV given before inoculation 
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Figure 12. Induction of 
monocyte recruitment to 
the nose by Spn 
colonisation is impaired 
by antecedent LAIV 
vaccination. (A) 
Recruitment of monocytes 
was measured in 106 
volunteers (n=20-31 in 
each group) by comparing 
the ratio of median of 
monocytes to epithelial cell 
in each timepoint 
compared to its baseline 
(day -4). (B) Median of 
monocyte to epithelial cell 
ratio of volunteers stratified 
by Spn colonisation status. 
Comparison between 
groups was made by 
Mann-Whitney test with p 
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Monocyte recruitment is associated with density of Spn only in TIV 
vaccinated. 
 
In order to investigate if the monocyte infiltration observed was associated 
with the increase in Spn density in the nasal mucosa, we performed correlation 
tests by using the maximum Spn density and maximum ratio of monocytes in the 
nasal mucosa in a subset of 45 colonised volunteers of the Antecedent LAIV-
EHPC study (TIV n=22, LAIV n=23). We demonstrated that the peak in monocyte 
numbers correlates with Spn density in the TIV- (p=0.016, R2=0.64, Figure 13A), 
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Figure 13. Monocyte recruitment is associated with density of Spn only in TIV vaccinated 
group. Levels of maximum Spn load are shown for the (A) TIV Spn+ (n=22) and (B) LAIV Spn+ 
group (n=23) and correlated with the maximum monocyte recruitment (fold-change to baseline). 
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Spn-induced activation of neutrophils in the nose is impaired by 
antecedent LAIV. 
 
To assess the levels of neutrophils we analysed CD66b, a marker for 
active neutrophils 319,320, in 106 volunteers divided in the groups. In addition, we 
measured the average median fluorescence intensity of CD66b from neutrophil 
(MFI of CD66b) to test the intensity of this marker. 
We observed that neither Spn colonisation nor influenza vaccination 
significantly alters the number of active neutrophils recruited to the nasal mucosa 
(Figure 14A, 14B). However, in TIV Spn-, the number of active neutrophils were 
slightly higher at day +2 when compared to baseline (Day +2 with median MFI of 
8534,8 and IQR 6495-14560 vs Day -4 with median 6846,6 and IQR 5260-11101, 
p=0.002, Figure 14C). Such a response was impaired in the LAIV group. When 
compared by Spn colonisation status, no significant differences in neutrophil 
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Figure 14. Spn-induced activation of active neutrophils in the nose is impaired by 
antecedent LAIV. Recruitment of neutrophils was measured in 106 volunteers with groups 
stratified by vaccination status (TIV or LAIV) and Spn colonisation (Spn-, non-colonised, and 
Spn+, colonised): TIV Spn- (n=31), TIV Spn+ (n=20), LAIV Spn- (n=29) and LAIV Spn+ (n=26). 
We compared (A) the median of neutrophils to epithelial cell ratio in each timepoint to baseline 
(day -4). (B) Median of neutrophils to epithelial cell ratio in volunteers stratified by Spn colonisation 
status (Spn- and Spn+). (C) Activation of neutrophils was assessed by comparing the median of 
MFI of CD66b in each timepoint to baseline. (D) Median of MFI of CD66b was compared between 
groups stratified by Spn colonisation. Comparisons within groups were performed by using 
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Antecedent LAIV induces activation of T-cells in the human nose. 
 
We examined T-cell recruitment to the nasal mucosa, comparing 106 
volunteers divided in groups considering vaccine and Spn colonisation status. 
Additionally, activation of T-cells was determined by analysing T-cell populations 
positive for the marker HLA-DR. 
Similar to neutrophils, neither the influenza vaccines nor Spn colonisation 
induced significant recruitment of CD3+ T-cells to the nose (Figure 15A and 15B). 
Nevertheless, antecedent LAIV induced T-cell activation independent of Spn 
colonisation status. LAIV administration before the bacterial challenge resulted to 
a peak of T cell activation 10 days (LAIV Spn+, day +7 median 1.3-fold increase, 
p=0.039) and 13 days after vaccination (LAIV Spn+, day +9, median 1.2-fold 
increase, p=0.042), whereas non-colonised subjects demonstrated a similar peak 
after 7 days (LAIV Spn-, median 1.3-fold increase, p=0.007) with another median 
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Figure 15. Antecedent influenza vaccines and Spn colonisation do not affect T-
cell recruitment to the human nasal lumen. (A) Nasal recruitment of T-cells was 
measured in 106 volunteers divided into groups: TIV Spn- (n=31), TIV Spn+ (n=20), 
LAIV Spn- (n=29) and LAIV Spn+ (n=26). We compared the (A) Median of T-cells to 
epithelial cell ratio in each timepoint to baseline (day -4) within groups using Wilcoxon 
test. (B) Median of T-cells to epithelial cell ratio in volunteers stratified by Spn 
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Figure 16. Antecedent LAIV, but not TIV, induces activation of T-cells in the human nose. 
Activation of T-cells was measured by comparing median percentage of HLA-DR+ T-cells in 106 
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4.3.2 Concurrent LAIV 
 
During the Concurrent LAIV-EHPC study, 194 volunteers were inoculated 
with Spn and vaccinated with either TIV (n=97) or LAIV (n=97) 3 days later. Nasal 
cells were sampled by curettage on days -5 (baseline), +2 (no vaccine), +6, +9, 
+27 relative to Spn inoculation. To perform the analysis, subjects were stratified 
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Spn colonisation of the nasopharynx induce neutrophil activation. 
 
For assessment of monocyte recruitment in nasal mucosa, we compared 
the median of monocytes to epithelial cell ratio in each timepoint to baseline using 
extracellular staining and flow cytometry analysis. Contrarily to the Antecedent 
study, no nasal recruitment of monocytes was observed after influenza 
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Figure 17. Induction of monocyte recruitment to the nose by Spn colonisation 
is affected by influenza vaccination.  (A) Recruitment of monocytes was 
measured in 99 volunteers (n=24-27) by comparing the ratio of median monocytes 
to epithelial cell in each timepoint compared to its baseline (day -5). (B) Median of 
monocyte to epithelial cell ratio of volunteers stratified by Spn colonisation status 
(Spn- and Spn+). Comparison within groups was made by Wilcoxon test and 
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Neutrophil levels were assessed in the same way by using the ratio of 
neutrophils to epithelial cells ratio in each timepoint. The concurrent influenza 
vaccines did not affect significantly the number of neutrophils at the nasal lumen 
(Figure 18A). However, in non-colonised (Spn-) group, levels of neutrophils were 
reduced by median 2.5-fold 27 days post Spn challenge when compared to 
baseline (p=0.046, Figure 18B). 
In response to Spn colonisation, LAIV Spn+ had a significant increase in 
neutrophil activation 2 days post-inoculation and before influenza vaccination 
(median 1.4-fold increase, p=0.048, Figure 18C). Although, the same pattern of 
neutrophil activation was observed in TIV Spn+, this increase did not differ 
significantly from the baseline. As these 2 groups received the influenza vaccine 
at Day 3 post pneumococcal inoculation, they can be pooled together up to Day 
2. Therefore, when volunteers were stratified by colonisation status, it was shown 
that indeed Spn induced neutrophils activation 2 days after inoculation (Spn+, 
median 1.66-fold increase, p<0.0001, Figure 18D). The induction was sustained 
6 days post-inoculation (median 1.4-fold increase, p=0.013), increasing further 
after 9 days (median 1.8-fold increase, p=0.022). 
Notably, differences in neutrophils activation were already significant at 
baseline (day -5), with TIV Spn+ being a median 1.5 and 1.6 times higher when 
compared to TIV Spn- (p=0.040) and LAIV vaccinated groups, respectively (vs 
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Figure 18. Spn colonisation of the nasopharynx induces neutrophil activation. (A) 
Recruitment of neutrophils was measured in 99 volunteers (n=24-27) by comparing the median 
of neutrophils to epithelial cell ratio in each timepoint to baseline (day -5) within groups using 
Wilcoxon test. (B) Median of neutrophils to epithelial cell ratio was measured in volunteers 
stratified by Spn colonisation status (Spn- and Spn+). The groups were compared in each 
timepoint by Mann Whitney test. (C) Activation of neutrophils was measured by comparing the 
median MFI of CD66b in each timepoint to baseline using Wilcoxon test and between groups 
using Mann Whitney test, with *p≤0.05. (D) MFI of CD66b stratified by Spn colonisation using 
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LAIV in Spn colonised alters T-cell subsets induction and T-cell 
activation. 
 
We investigated CD3+ T-cell recruitment to the nose, as well as activation 
of T- cells using the marker HLA-DR in 99 volunteers divided in groups: TIV Spn- 
(n=24), TIV Spn+ (n=27), LAIV Spn- (n=24) and LAIV Spn+ (n=24).  
Interestingly, concurrent LAIV and Spn colonisation prevented a small 
median increase of 1.1-fold in T-cells levels 27 days post-inoculation which was 
significant in TIV Spn- (p=0.013, Figure 19A, Figure 19B). Interestingly, at this 
timepoint, the group TIV Spn- showed higher CD4+ T-cells levels, presenting 
median 1.6-fold increase in levels (p=0.013, Figure 20A) as well as a decrease 
of CD8+ T-cells with a small median 1.1-fold reduction (p=0.007, Figure 20B). 
Importantly, LAIV Spn- showed a significant decrease in T-cell activation 
2 days after Spn inoculation which was impaired in Spn colonised (median 1.4-
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Figure 19. Late increase of T-cells in Spn non-colonised. (A) Nasal 
recruitment of T-cells was measured in volunteers (n=24-27) by 
comparing the median of T-cells to epithelial cell ratio in each timeline to 
baseline (-5) within groups using Wilcoxon test with *p≤0.05. (B) Median 
of T-cells to epithelial cell ratio in volunteers stratified by Spn colonisation 
status (Spn-, n=60, and Spn+, n=46) using Mann Whitney test for 
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Figure 20. LAIV and Spn colonisation alters late CD4+ T-cells decrease and CD8+ increase. 
(A) Nasal recruitment of T-cells was measured in volunteers (n=24-27) by comparing the median 
of CD4+ T-cells to epithelial cell ratio in each timeline to baseline (-5). (B) Median of CD8+ T-cells 
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Figure 21. LAIV and Spn colonisation alters T-cell activation. (A) Activation of T-cells was 
measured by comparing median percentage of HLA-DR positive T-cells using Wilcoxon test for 
each timepoint to baseline (day -5) with *p≤0.05. Groups were stratified by vaccination and Spn 
colonisation status (n=24-27). (B) Fold-change of median percentage of HLA-DR positive T-cells 
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We also assessed the recruitment of DCs, using the markers BDCA1 
(CD1c) for inflammatory DCs and BDCA-2 (CLEC4C) for plasmacytoid DCs. 
BDCA-1+ DCs is a subset of cells that present dendritic morphology and can 
induce robust T-cell stimulation 321, whereas BDCA-2+ DCs can affect the innate 
immune responses via TNF- and IFN- production 322. The median of BDCA-1+ 
and BDCA-2+ cells to epithelial cell ratio was measured in each timepoint and 
compared to baseline demonstrating no significant differences in cell recruitment 
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Figure 22. Concurrent influenza vaccines and Spn colonisation do not significantly affect 
BDCA-1+ and BDCA-2+ DC levels in the human nasal mucosa. (A) Nasal recruitment of DCs 
was measured in volunteers (n=24-27) by comparing the (A) median of BDCA1+ DC. (B) median 
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4.4 Discussion 
 
The immunological mechanisms that control Spn colonisation and the 
impact of LAIV vaccination thereon have been studied extensively in mice 
76,186,323,324 but remain poorly understood in humans. The Antecedent and 
Concurrent LAIV-EHPC studies allowed us to study the recruitment of immune 
cells to the human nasopharynx following Spn inoculation and influenza 
immunisation. We demonstrated that when LAIV proceeds Spn colonisation 
affects cellular responses, such monocytes recruitment in the nasal lumen, as 
well as activation of neutrophils and T-cells. Additionally, Spn colonisation 
induced neutrophil activation and impaired T-cells activation and abundance in 
the nasal mucosa.  
The human nasopharynx, the site where pneumococcal colonisation 
occurs, is equipped with both epithelial and immune cells that mount responses 
to S. pneumoniae 306. In mice, nasal mucosal immune responses to Spn are 
described by classic activation of macrophages and increase in regulatory T-cells 
(T-reg) levels 92. During a colonisation episode, monocytes together with 
neutrophils are supposed to contribute to the control of Spn density, as 
demonstrated by the recruitment of these type of cells in mice deficient for 
macrophage 325,122,326. In line with the data deriving from mice 327, in healthy 
adults monocytes were recruited to the nasal mucosa after Spn colonisation. 
Monocytes recruitment peaked at Day 9 post the bacterial challenge in the control 
group. On the other hand, primary infection with LAIV, which leads to a transient 
influenza virus replication in the nasal mucosa, impaired monocyte recruitment in 
those colonised with Spn. Moreover, only in the control group Spn density was 
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attenuated influenza viruses contained in the vaccine possibly disrupts host 
cytokine and chemokine signalling and subsequently impairs monocyte 
recruitment. 
Our finding on the effect of LAIV in Spn colonised individuals corroborate 
with studies in which LAIV impact monocyte recruitment similarly to the wild-type 
influenza infection in mice, offering an explanation for the association of LAIV 
administration with increase in Spn acquisition and bacterial load found in human 
studies 318,328. Monocytes seems to be key cells in controlling nasopharyngeal 
pneumococcal colonisation 94 329 and inhibition of their recruitment to the nasal 
mucosal has been associated with reduced bacterial clearance 108,330. Although 
our results are robust, they may not be translated accurately to young children, 
as monocyte recruitment to the nasal mucosa is observed during influenza 
infection 331. Interestingly, although concurrent LAIV was shown to increase 
levels of monocytes, recruitment of these immune cells was not significant. A 
possible explanation for this discrepancy between the two studies is that baseline 
levels of resident macrophages were approximately the double in the Antecedent 
LAIV study when compared to the Concurrent LAIV study. Further, in the 
presence of Spn or when undergo apoptosis, resident macrophages signal for 
the recruitment of blood circulating monocytes, which could further explain the 
increased concentration of monocytes in volunteers who already displayed high 
levels at baseline. In addition, reduced Spn density and colonisation periods were 
reported in the Concurrent study when compared to the Antecedent 50 which can 
also affect monocyte recruitment. 
Unlike monocytes, high levels of neutrophils can be found in healthy 
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17A contributing to neutrophil recruitment to the nasal mucosa 94. In the first 24 
hours of Spn colonisation, neutrophils perform essential roles in controlling the 
infection mainly through serine proteases 332 as well as degranulation, production 
of reactive oxygen and nitrogen species, and pro-inflammatory cytokines 92,327.  
Additionally, co-infection studies with antecedent wild-type influenza virus 
and Spn in mice demonstrate impairment in recruitment of neutrophils due to 
reduction in KC and chemokine MCP-1 expression, critical for infection control 
186, as well as increased expression of anti-inflammatory cytokine IL-10, 
commonly produced by CD8+ T-regs after viral clearance 92,127,188. In contrast to 
this mechanism described in murine models of antecedent influenza co-infection, 
we did not observe neutrophil recruitment to the nose following Spn colonisation. 
This underlies the importance of confirmation of data with the attenuated virus 
and human data to elucidate the impact of LAIV.  
However, when Spn colonised the nasal mucosa prior to influenza 
vaccination, it induced activation of neutrophils during 9 days after inoculation, 
indicating that the co-infection elicits additional immune mechanisms for control 
of both pathogens. The results corroborate neutrophil studies in mice which have 
demonstrated that Spn infection within 3 days of influenza infection induce 
clearance whereas co-infection within 6 to 10 days conferred inefficient bacterial 
control and colonisation of the nasopharynx 192. Importantly, although neutrophils 
are present in the nasal lumen of children of 9 to 11 years old 333, the results may 
not be transferable to younger ages considering studies in which Spn-induced 
neutrophils are not detected in the nasal mucosa of naive mice 94. Additionally, 
the depletion of these immune cells did not increase susceptibility to 
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When the innate immunity is not enough to allow for effective viral 
clearance, adaptive responses are also induced in the nasopharynx. Murine 
models show that in the human upper airways, viral pathogens are recognised 
through pattern recognition receptors (PRRs) such as TLRs and intracellular viral 
sensors that in turn induce adaptive responses 196, eliciting secretory antibodies 
and T-cells with mucosal homing properties, especially influenza-specific CD8+ 
T-cells, common in natural influenza infections 187. Here, we demonstrate that in 
human adults the presence of the attenuated influenza viruses did not affect T-
cell recruitment, although it induced T-cell activation. Increased activation 
indicates that the attenuated virus is presented to the host as a natural infection 
by producing intracellular influenza antigens eliciting T-cell responses similar to 
the wild-type influenza 335. 
In conclusion, the results presented in this chapter address important 
questions about the immune responses that control and clear Spn and how LAIV 
can alter these immune mechanisms, using for the first time an experimental 
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5.1 Introduction 
 
A stable and asymptomatic Spn colonisation is not uncommon in children 
and adults, and provide benefits to the host as it develops cellular and adaptive 
immunity in the nasopharynx and systemically 49,62 . The immunising 
asymptomatic colonisation is maintained by a fine balance between pro- and anti-
inflammatory cytokines 92.  
However, influenza virus has the ability to interact with and modify the host 
nasal environment 196, and can leave individuals susceptible to uncontrolled Spn 
colonisation 262. First shown in a ferret model by McCullers 273, wild-type influenza 
virus causes deregulation between immune tolerance and inflammatory 
responses, which can lead to damage in nasal epithelium 190 and, in turn, facilitate 
Spn adhesion to cells and impairment of cellular protection against the bacteria 
76,92,274. Spn replicated continuously in the nose, increasing density and bacterial 
infiltration to the lungs as well as inducing more cytokines, chemokines and 
antimicrobial peptides 132,188,270. These elicited cytokines are shown to have a 
wide range of effects during co-infection in mice, acting on both innate and 
adaptive processes of the immune system 76,92,274. They can affect recruitment of 
immune cells, including monocytes, neutrophils and T-cells, as well as their 
activation 92,132,186,188,262,270,271.  
Furthermore, influenza vaccination with live attenuated virus – although an 
effective strategy to prevent infection in children 213 – also influence host immune 
responses to Spn, affecting Spn acquisition and density, transmission and 
susceptibility to invasive disease 281 due to its mimicry of wild-type influenza 
natural replication in the nasopharynx, known as viral shedding. Similarly to 
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induced deregulated cytokine responses in the nasopharynx 274, which highlights 
the necessity of validation of these findings in human. Herein, we used a 
controlled human LAIV-Spn co-infection model to investigate the cytokine 
responses elicited to Spn colonisation and how these responses are altered by 
either a primary or a simultaneous influenza viral infection.  
 
5.2 Material and methods 
5.2.1 Volunteer recruitment, vaccination and inoculation 
75 adult volunteers were recruited for the Antecedent and Concurrent 
studies (as described in Section 2.2) and received influenza vaccination (LAIV or 
TIV as control) and were inoculated with live Spn using EHPC. Individuals were 
vaccinated 3 days previous to Spn inoculation in the Antecedent study and 3 days 
after in the Concurrent study (Section 2.3 and 2.5.4).  
 
5.2.2 Nasosorption collection 
An adsorptive matrix strip was used in the nasal septum of volunteers for 
collection of nasal fluid and stored at -80oC (Section 2.5.7). 
 
5.2.3 Luminex and statistical analysis 
As described in Section 2.6.7 nasal fluid was washed and prepared for 
Luminex Human Cytokine 30-plex per manufacturer’s instructions. Results 
obtained were processed and analysed by a LX200 and xPonent 3.1 software. 
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5.3 Results 
In the Antecedent study, 75 volunteers were vaccinated with LAIV (n=38) 
or TIV as control (n=37) and 3 days later inoculated intranasally with live Spn. 
Volunteers were stratified into groups: TIV Spn- (n=19), TIV Spn+ (n=18), LAIV 
Spn- (=19) and LAIV Spn+ (n=19). NS was collected at baseline (day -4), day +0, 
+2, +7, +9 and +29 relative to Spn inoculation. Levels of 30 cytokines were 
measured in the nasal lining fluid by Luminex. 
In the Concurrent study, 56 volunteers were inoculated with live Spn, 
following vaccination with LAIV (n=28) or TIV (n=28) 3 days later. NS was 
collected at baseline (day -5) and at days +6, +9 and +27 relative to inoculation 
(or 3, 6 and 24 days after vaccination). Levels of 30 cytokines were measured in 
the nasal lining fluid by Luminex, however, only 6 volunteers became colonised 
in this subset of volunteers. Therefore, stratification for analysis was done 
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LAIV induces pro-inflammatory cytokines in nasopharynx, 
especially in Spn colonised. 
 
Firstly, we investigated the cytokine profile elicited by concurrent influenza 
vaccines in the human nasal mucosa in volunteers challenged by Spn but not 
colonised.  
Three days after vaccination (day +6), volunteers in the control group 
induced a median 1.4-fold decrease in levels of pro-inflammatory cytokine IL-1β 
(p=0.033, Figure 23A) and 6 days after (day +9) a median 2-fold decrease in GM-
CSF (p=0.049, Figure 23B).  
In contrast to TIV, LAIV vaccination elicited increase of IL-1β levels 3 days 
after vaccination (day +6) (median 1.2-fold increase) (p=0.049, Figure 24A). 
Moreover, we observed that LAIV induced a high pro-inflammatory cytokine 
response in the nose, with median 1.6-fold increase of IFN- and MIP-1 
(p=0.013, Figure 24B and Figure 24C), median 1.9-fold increase of MIP-1β levels 
(p=0.009, Figure 24D) and median 2.5-fold increase of TNF- levels (p=0.011, 
Figure 24E).  
Six days after vaccination (day +9), LAIV group maintained a similar to day 
+6 induction of IL-1β, MIP-1, TNF- and MIP-1β levels (IL.1β: median 1.3-fold 
increase, p=0.021, Figure 24A; MIP-1: median 1.5-fold increase, p=0.048, 
Figure 24C; TNF-: median 1.5-fold increase, p=0.026, Figure 24E; MIP.1β: 
median 1.5-fold increase, p=0.035, Figure 24D) but not for IFN-. Additional pro-
inflammatory cytokine response was elicited with increases in levels of MCP-1, 
IL-6 and IL-8 (MCP-1: median 1.8-fold increase, p=0.010, Figure 25A; IL-6: 
median 1.9-fold increase, p=0.035, Figure 25B; IL-8: median 1.3-fold increase, 
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p=0.035, Figure 25C). Moreover, at day 24 after influenza vaccination (day +29), 
TNF- levels were sustained at levels similar to those observed at day +6 and +9 
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Figure 23. TIV vaccinated group exhibits decrease in pro-inflammatory cytokines IL-1β and 
GM-CSF in the nasopharynx. Levels of (A) IL-1β and (B) GM-CSF measured in nasal lining of 
volunteers vaccinated with TIV (n=28) were compared at each timepoint to baseline (day -5) by 


























































































































Figure 24. LAIV vaccinated group exhibits increase in pro-inflammatory cytokines in the 
nasopharynx. Levels of (A) IL-1β, (B) IFN-, (C) MIP-1, (D) MIP-1β and (E) TNF- measured 
in nasal lining of volunteers vaccinated with LAIV (n=28) were compared at each timepoint to 
baseline (day -5) by Wilcoxon test with *p≤0.05 and **p<0.01. Medians and interquartile range of 
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Figure 25. LAIV vaccinated group exhibits increase in pro-inflammatory cytokines in the 
nasopharynx. Levels of (A) MCP-1, (B) IL-6 and (C) IL-8 measured in nasal lining of volunteers 
vaccinated with LAIV (n=28) were compared at each timepoint to baseline (day -5) by Wilcoxon 
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Next, we examined the cytokine profile elicited in a second set of 
volunteers by antecedent influenza vaccines followed by Spn inoculation in the 
nose, with groups stratified by vaccination and colonisation status.  
Notably, antecedent LAIV in absence of Spn colonisation (day +0) induced 
cytokines IL-6 and MIG, as LAIV Spn- presented median 1.4- and 2.5-fold 
increase of IL-6 and MIG levels, respectively (p=0.021 and p=0.003, Figure 26A 
and 26B, respectively). Moreover, LAIV induced MCP-1 and TNF- secretion in 
the nasopharynx, but only MCP-1 levels were maintained up to Day 9 post 
inoculation in the LAIV Spn- (MCP-1, median 1.3-fold increase, p=0.029; TNF-, 
median 1.9-fold increase, p=0.030, Figure 27A and 27B). 
Additionally, in LAIV Spn-, Spn challenge also induced the secretion of the 
pro-inflammatory cytokines MIP-1, MIP-1β, IL-1β and RANTES 2 days after 
challenge (MIP-1, median 1.3-fold increase, p=0.024; MIP-1β, median 1.4-fold 
increase, p=0.036; IL-1β, median 1.7-fold increase, p=0.004; RANTES, median 
2.9-fold increase, p=0.026, Figure 28A, 28B, 28C and 28D respectively). 
Seven days after inoculation, volunteers continued to express Spn-
induced IL-1β although no other cytokine increase was demonstrated (median 
1.3-fold increase, p=0.020, Figure 28C). On the other hand, 9 days post-
inoculation another peak of pro-inflammatory cytokine levels was observed in this 
group with induction of MIG, MCP-1, IL-1β and RANTES (MIG, median 1.7-fold 
increase, p=0.030; MCP-1, median 1.4-fold increase, p=0.010, IL-1β, median 1.5-
fold increase, p=0.044; RANTES, median 2.5-fold increase, p=0.018. Figures 
26B, 27A; 28C and 28D respectively). 
The inflammation profile observed at day +0 in LAIV Spn+ was similar to 
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and 2.2-fold increase, respectively (p=0.012 and p=0.023, Figure 29A and 29B, 
respectively). Furthermore, LAIV with the influence of Spn, induced the 
production of cytokines IFN-, MIP-1, MIP-1β and IP-10 (median 1.1-, 1.2-, 1.3- 
and 3.6-fold increase, respectively. IFN-, p=0.009; MIP-1, p=0.023; MIP-1β, 
p=0.035; IP-10, p<0.001, Figure 30A, 30B, 30C and 30D respectively). 
Interestingly, LAIV Spn+ LAIV-induced IL-6 cytokine exhibited increased levels 5 
days after LAIV administration (median 1.8-fold increase, p<0.001, Figure 29A). 
Also 5 days after LAIV, in volunteers of the LAIV Spn+ group, Spn 
colonisation induced a median 1.4-fold increase in IL-1β (p=0.003, Figure 31). 
These volunteers also demonstrated higher levels of MIP-1 and MIP-1β (Figure 
30B and 30C), however this induction started before Spn inoculation (MIP-1, 
median 1.4-fold increase, p=0.038; MIP-1β, median 1.6-fold increase, p=0.017). 
Additionally, likewise responses at day +0, 2 days after Spn challenge, LAIV-
vaccinated and colonised were still the only group to induce IFN- (median 1.2-
fold increase, p=0.001, Figure 30A) and even higher levels of IP-10 (median 4.8-
fold increase, Figure 30D). 
Opposite to non-colonised, LAIV Spn+ did not show great cytokine level 
increases after 2 days since colonisation. In this group, we also observed only a 
moderate increase in IFN- induction 7 and 9 days post-inoculation (day +7, 
median 1.1-fold increase, p=0.028, day +9, median 1.1-fold increase, p=0.018, 
Figure 30A). 
Interestingly, the TIV Spn- exhibited an induction of MIG before (day +0), 
7 and 9 days after Spn challenge, which was not observed in the first set of 
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p=0.010; day +9, median 1.9-fold increase, p=0.026. Figure 32A) as well as IP-

























































Figure 26. Antecedent LAIV induces pro-inflammatory cytokines IL-6 and MIG in 
nasopharynx of non-colonised volunteers. Levels of (A) IL-6 and (B) MIG were measured in 
nasal lining of volunteers vaccinated with antecedent LAIV and not colonised by Spn (LAIV Spn-
, n=18-19). Results were compared at each timepoint to baseline (day -4) by Wilcoxon test with 
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Figure 27. Antecedent LAIV induces pro-inflammatory cytokines MCP-1 and TNF- in 
nasopharynx of non-colonised volunteers. Levels of (A) MCP-1 and (B) TNF- were 
measured in nasal lining of antecedent LAIV-vaccinated and non-colonised volunteers (LAIV Spn-
, n=18-19) and compared at each timepoint to baseline (day -4) by Wilcoxon test with *p≤0.05. 
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Figure 28. Antecedent LAIV induces additional pro-inflammatory cytokines in nasopharynx 
of non-colonised volunteers. Levels of (A) MIP-1, (B) MIP-1β, (C) IL-1β and (D) RANTES were 
measured in nasal lining of volunteers vaccinated with antecedent LAIV and not colonised by Spn 
(LAIV Spn-, n=18-19). Results were compared at each timepoint to baseline (day -4) by Wilcoxon 
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Figure 29. Antecedent LAIV induces pro-inflammatory cytokines IL-6 and MIG in 
nasopharynx of Spn colonised volunteers. Levels of (A, B) IL-6 and (C, D) MIG were measured 
in nasal lining of volunteers vaccinated with antecedent LAIV and colonised by Spn (LAIV Spn+, 
n=18-19). Results were compared at each timepoint to baseline (day -4) by Wilcoxon test with 
*p≤0.05, **p<0.01 and ***p<0.001. In A and C, medians and interquartile range of each timepoint 
are shown. In B and D each line represents one volunteers and each point the result of a single 
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Figure 30. Antecedent LAIV induces additional pro-inflammatory cytokines in nasopharynx 
of Spn colonised volunteers. Levels of (A, B) IFN-, (C, D) MIP-1, (E, F) MIP-1β and (G, H) 
IP-10 were measured in nasal lining of volunteers vaccinated with antecedent LAIV and colonised 
by Spn (n=18-19) and compared at each timepoint to baseline (day -4) by Wilcoxon test with 
*p≤0.05, **p<0.01 and ***p<0.001. In A, C, E and G medians and interquartile range of each 
timepoint are shown. In B, D, F and H each line represents one volunteers and each point the 























































Figure 31. Antecedent LAIV induces pro-inflammatory cytokine IL-1β in nasopharynx of 
Spn colonised volunteers. Levels of IL-1β was measured in nasal lining of volunteers 
vaccinated with antecedent LAIV and colonised by Spn (LAIV Spn+, n=18-19). Results were 
compared at each timepoint to baseline (day -4) by Wilcoxon test with *p≤0.05 and **p<0.01. (A) 
Medians and interquartile range of each timepoint are shown. (B) Each line represents one 
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Figure 32. Non-colonised volunteers show induction of pro-inflammatory cytokines MIG 
and IP-10 in the nose . Levels of (A) MIG and (B) IP-10 were measured in nasal lining of 
volunteers in the control group that cleared Spn in the nasopharynx (TIV Spn-, n=18-19) and 
compared at each timepoint to baseline (day -4) by Wilcoxon test with *p≤0.05 and **p<0.01. 
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Antecedent LAIV-induction of cytokines that regulate adaptive 
immunity diverge between Spn colonised and non-colonised 
volunteers 
 
We assessed the levels of cytokines related to regulation of the adaptive 
immune responses after concurrent influenza vaccine administration in 
volunteers previously challenged with Spn, but not colonised. 
LAIV-vaccinated volunteers showed increase in cytokines IFN- and IL-15 
3 days after vaccination (day +6, IFN-: median 1.4-fold increase, p=0.035, Figure 
33A; IL.15: median 1.3-fold increase, p=0.041, Figure 33B). Six days after LAIV 
(day +9), the vaccine induced a moderate increase in IL-2R, IL-2 and IL-12 levels 
(IL-2R: median 1.1-fold increase, p=0.018, Figure 34A; IL-2: median 1.2-fold 
increase, p=0.073, Figure 34B; IL-12: median 1.5-fold increase, p=0.012, Figure 
34C), as well as for IFN- and IL-15 (IFN-: median 1.4-fold increase, p=0.047, 
Figure 33A; IL-15: median 1.1-fold increase, p=0.025, Figure 33B). Volunteers 
who received TIV had a slight increase in IL-4 6 days after vaccination (day +9, 
median 1.1-fold increase, p=0.018, Figure 35A). A similar increase of IL-4 was 

























































Figure 33. LAIV vaccinated show increase in cytokines IFN- and IL-15 in the nasopharynx. 
Levels of (A) IFN- and (B) IL-15 measured in nasal lining of volunteers vaccinated with LAIV 
(n=28) were compared at each timepoint to baseline (day -5) by Wilcoxon test with *p≤0.05. 
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Figure 34. LAIV vaccinated show increase in cytokines that regulate adaptive responses 
in the nasopharynx. Levels of (A) IL-2R, (B) IL-2 and (C) IL-12 measured in nasal lining of 
volunteers vaccinated with LAIV (n=28) were compared at each timepoint to baseline (day -5) by 
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Figure 35. TIV- and LAIV-vaccinated show increase in the cytokine IL-4 in the nasopharynx. 
Levels of IL-4 was measured in nasal lining of volunteers vaccinated with (A) TIV (n=28) and (B) 
LAIV (n=28). Results compared at each timepoint to baseline (day -4) by Wilcoxon test with 
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Further, we analysed a second set of volunteers, vaccinated with influenza 
vaccines followed by Spn challenge, and stratified into groups regarding 
vaccination and colonisation status.  
Before Spn inoculation (day +0), both groups of volunteers vaccinated with 
LAIV demonstrated a moderate induction of IL-4 (LAIV Spn-, median 1.2-fold 
increase, p=0.021, Figure 36A; LAIV Spn+, median 1.4-fold increase, p=0.008, 
Figure 36B), IL-2 (LAIV Spn-, median 1.1-fold increase, p=0.026, Figure 36C; 
LAIV Spn+, median 1.4-fold increase, p=0.001, Figure 36D), IFN- (LAIV Spn-, 
median 1.2-fold increase, p=0.009, Figure 37A; LAIV Spn+, median 1.3-fold 
increase, p<0.001, Figure 37B) and IL-15 (LAIV Spn-, median 1.3-fold increase, 
p=0.001; Figure 37C; LAIV Spn+, median 1.2-fold increase, p=0.024, Figure 
37D).  
Interestingly, in LAIV Spn- the vaccine also conferred a slight increase in 
IL-12 (median 1.2-fold increase, p=0.035, Figure 38A) and IL-2R levels (p=0.021, 
Figure 38B), which was not observed in LAIV Spn+. 
 Two days after Spn inoculation, LAIV continued to similarly induce 
cytokines expressed at day +0 in both non-colonised and Spn colonised. 
Importantly and similarly to the first set of volunteers vaccinated with antecedent 
vaccines, we observed that volunteers vaccinated with LAIV showed increase in 
IL-4 levels (LAIV Spn-: p=0.003, Figure 36A; LAIV Spn+: p=0.025, Figure 36B). 
Moreover, TIV Spn- demonstrated instead a median 1.3-fold decrease in IL-4 
(p=0.042, Figure 39).  
Only in the groups vaccinated with LAIV we observed moderate inductions 
of IL-2, IFN-, IL-15 2 days after inoculation (LAIV Spn-: IL-2, median 1.1-fold 
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37A; IL-15, median 1.5-fold increase, p=0.006, Figure 37C; LAIV Spn+: IL-2, 
median 1.3-fold increase, p=0.004, Figure 36D; IFN-, median 1.3-fold increase, 
p=0.002, Figure 37B; IL-15, median 1.4-fold increase, p=0.021, Figure 37D). 
In addition, in non-colonised group IL-12 induction by LAIV was similar to 
this observed before the Spn challenge (day +0) (median 1.5-fold increase, 
p=0.035, Figure 38A). In the LAIV Spn+ group such an induction was observed 
only early post the challenge (median 1.2-fold increase, p=0.012, Figure 40A). 
Importantly, LAIV Spn+ were the only group to elicit a median increase of 1.5-fold 
in IL-17A levels (p=0.018, Figure 40B). 
 Nine days after inoculation, LAIV in LAIV Spn blocked an increase in IL-4 
(1.2-fold increase, p=0.021, Figure 36A), first induced by LAIV in non-colonised 










































































































Figure 36. Antecedent LAIV induce cytokines IL-2 and IL-4 in the nose. Levels of cytokines 
measured in nasal lining of volunteers vaccinated with LAIV (n=18-19). IL-4 was measured in 
volunteers (A) not colonised by Spn (LAIV Spn-) and (B) colonised by Spn (LAIV Spn+). Similarly, 
IL-2 was measured in (C) not colonised and (D) colonised. Results were compared at each 
timepoint to baseline (day -4) by Wilcoxon test with *p≤0.05 and **p<0.01 and medians and 











































































































Figure 37. Antecedent LAIV induce cytokines IFN- and IL-15 in the nose. Levels of cytokines 
measured in nasal lining of volunteers vaccinated with LAIV (n=18-19). IFN- was measured in 
volunteers (A) not colonised by Spn (LAIV Spn-) and (B) colonised by Spn LAIV Spn) . IL-15 was 
measured in (C) not colonised and (D) colonised. Results were compared at each timepoint to 
baseline (day -4) by Wilcoxon test with *p≤0.05, **p<0.01 and ***p<0.001 and medians and 




















































Figure 38. Antecedent LAIV induce cytokines IL-12 and IL-2R in the nose of non-colonised 
volunteers. Levels of (A) IL-12 and (B) IL-2R were measured in nasal lining of volunteers 
vaccinated with LAIV and not colonised by Spn (LAIV Spn-, n=18-19) and compared at each 
timepoint to baseline (day -4) by Wilcoxon test with *p≤0.05. Medians and interquartile range of 
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Figure 39. Non-colonised volunteers show induction of IL-4 in the nose . Levels of IL-4 was 
measured in nasal lining of volunteers in the control group that cleared Spn in the nasopharynx 
(TIV Spn-, n=18-19) and compared at each timepoint to baseline (day -4) by Wilcoxon test with 







































































Figure 40. Antecedent LAIV induce cytokine IL-12 and IL-17A in the nose of volunteers 
colonised by Spn. Levels of (A) IL-12 and (B, C) IL-17A were measured in nasal lining of 
volunteers vaccinated with LAIV and colonised by Spn (LAIV Spn+, n=18-19) and compared at 
each timepoint to baseline (day -4) by Wilcoxon test with *p≤0.05. In A and B, medians and 
interquartile range of each timepoint are shown. In C each line represents one volunteer and each 
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LAIV induces cytokines that regulate cell growth in the 
nasopharynx especially in Spn colonised. 
 
Here, we investigated how concurrent LAIV and TIV in volunteers 
previously challenged with Spn but not colonised affect the production of 
cytokines that regulate growth of granulocytes, neuronal, epidermal, epithelial B, 
T-, NK- and hematopoietic stem cells, as well as embryonic development, 
morphogenesis, tissue repair, angiogenesis. 
Three days after vaccination (day +6), LAIV induced a median 2-fold 
increase in EGF (p=0.035, Figure 41A) while TIV-vaccinated showed a median 
1.3-fold decrease (p=0.033, Figure 41B). In addition, LAIV induced a median 1.4-
fold increase in VEGF (p=0.021, Figure 42A). Further, at 6 days post-vaccination 
(day +9) TIV-vaccinated volunteers did not show increased cytokine levels while 
LAIV continued to induce a median 1.5 and 1.4-fold increase in EGF and VEGF, 
respectively (p=0.010, Figure 41B, and p=0.047, Figure 42B). Interestingly, TIV 
vaccinated showed decrease in levels of FGF-Basic 24 days after vaccination 





















































   
Figure 41. LAIV- and TIV- vaccinated show increase in cytokines EGF in the nasopharynx. 
Levels of EGF were measured in nasal lining of volunteers vaccinated with (A) LAIV (n=28) and 
(B) TIV (n=28). Results were compared at each timepoint to baseline (day -5) by Wilcoxon test 
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Figure 42. LAIV vaccinated show increase in cytokines VEGF in the nasopharynx. Levels 
of VEGF were measured in nasal lining of volunteers vaccinated with (A) LAIV (n=28) and (B) TIV 
(n=28) and compared at each timepoint to baseline (day -5) by Wilcoxon test with *p≤0.05. 
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Figure 43. LAIV vaccinated show increase in cytokine FGF-Basic in the nasopharynx. 
Levels of FGF-Basic were measured in nasal lining of volunteers vaccinated with LAIV (n=28). 
Results were compared at each timepoint to baseline (day -5) by Wilcoxon test with *p≤0.05 and 
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Additionally, we measured cytokine production in a second set of 
volunteers, vaccinated with antecedent LAIV and TIV followed by Spn challenge, 
and stratified in vaccination and colonisation status. 
Before Spn inoculation (day +0), LAIV induced only a median 1.4-fold 
increase in G-CSF in those volunteers who would not achieve colonisation post 
the bacterial challenge (p=0.001, Figure 44A). On the other hand, vaccination in 
LAIV Spn+ induced a median 1.6-fold increase in G-CSF (p=0.001, Figure 44B) 
along with median 1.2-fold increase in FGF-Basic and VEGF (p=0.010 and 
p=0.044, Figure 45A and 45B, respectively).  
Two days after Spn inoculation, LAIV in LAIV Spn- continued to induce G-
CSF (median 1.2-fold increase, p=0.009, Figure 44A) and started to express 
higher levels of FGF-Basic and EGF (FGF-Basic: median 1.8-fold increase, 
p=0.023, Figure 46A; EGF, median 1.7-fold increase, p=0.010, Figure 46B). In 
LAIV colonised volunteers induction of G-CSF, FGF-Basic and VEGF persisted 
in this timepoint (G-CSF, median 1.4-fold increase, p=0.009, Figure 44B; FGF-
Basic, median 1.2-fold increase, p=0.004, Figure 45A; VEGF, median 1.1-fold 
increase, p=0.040, Figure 45B) with additional induction of IL-7, only elicited in 
LAIV vaccinated after Spn challenge (median 1.3-fold increase, p=0.027, Figure 
47). 
Importantly, only EGF was elicited exclusively by TIV Spn+ (median 1.7-
fold increase, p=0.005, Figure 48) showing similar induction in LAIV Spn- (median 
1.3-fold increase, p=0.048, Figure 46B). Further, at 7 and 9 days post-inoculation, 
the control group did not show increase in EGF, however, LAIV Spn- 
demonstrated a LAIV-induced median 2-fold increase (p=0.020, Figure 46B). In 
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increase of a median 1.2-fold of G-CSF (LAIV Spn-: p=0.026, Figure 44A, LAIV 
Spn+: p=0.026, Figure 44B). Interestingly, this cytokine was induced by the 
attenuated influenza viruses since before Spn challenge at day +0. 
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Figure 44. Antecedent LAIV induce cytokine G-CSF in the nose of volunteers. Levels of G-
CSF was measured in nasal lining of volunteers vaccinated with LAIV and (A) not colonised and 
(B) colonised by Spn (n=18-19) and compared at each timepoint to baseline (day -4) by Wilcoxon 
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Figure 45. LAIV induces FGF-Basic and VEGF in the nasopharynx of Spn colonised 
volunteers. Levels of (A) FGF-Basic and (B) VEGF were measured in nasal lining of volunteers 
vaccinated with LAIV and colonised by Spn (LAIV Spn+, n=18-19) and compared at each 
timepoint to baseline (day -4) by Wilcoxon test with *p≤0.05 and **p<0.01. Medians and 
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Figure 46. LAIV induces cytokine FGF-Basic and EGF in the nasopharynx of non-colonised 
volunteers. Levels of (A) FGF-Basic and (B) EGF were measured in nasal lining of volunteers 
vaccinated with LAIV and not colonised by Spn (LAIV Spn-, n=18-19) and compared at each 
timepoint to baseline (day -4) by Wilcoxon test with *p≤0.05. Medians and interquartile range of 



























Figure 47. LAIV induces cytokine IL-7 in the nasopharynx of Spn colonised volunteers. 
Levels of IL-7 was measured in nasal lining of volunteers vaccinated with LAIV and colonised by 
Spn (LAIV Spn+, n=18-19) and compared at each timepoint to baseline (day -4) by Wilcoxon test 
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Figure 48. Spn colonised show increased levels of cytokine EGF in the nasopharynx. 
Levels of EGF was measured in nasal lining of volunteers in the control group colonised by Spn 
(TIV Spn+, n=18-19) and compared at each timepoint to baseline (day -4) by Wilcoxon test with 
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LAIV induction of anti-inflammatory cytokine response is 
impaired in the Spn colonised nasal mucosa 
 
Firstly, we assessed anti-inflammatory cytokines in the nasopharynx of 
volunteers challenged with Spn and not colonised, followed with vaccination with 
concurrent LAIV and TIV. Here, we demonstrated that LAIV induces only HGF, 6 
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Figure 49. TIV-vaccinated show increase in cytokine HGF in the nasopharynx. Levels of 
HGF was measured in nasal lining of volunteers vaccinated with TIV (n=28). Results were 
compared at each timepoint to baseline (day -5) by Wilcoxon test with *p≤0.05 and medians and 
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Secondly, another set of volunteers vaccinated with antecedent influenza 
vaccines followed with Spn challenge, were stratified into groups regarding 
vaccination and colonisation status. 
After vaccination but before inoculation (day +0), LAIV resulted in a 
considerable increase in IL-10 levels (median 3.7-fold increase, p=0.006, Figure 
50A) in LAIV Spn-. This induction was unique, as was not observed in any other 
group. Two days after challenge, a median 2.8-fold increase in IL-10 was still 
observed (p=0.002). Additionally, an induction of HGF (median 1.3-fold increase, 
p=0.009, Figure 50B) was observed in the same group post Spn inoculation.  
Interestingly, in the control group, Spn colonisation prevented an increase 
of anti-inflammatory cytokine IL-10 7 days post-inoculation, observed in TIV Spn- 
(median 1.4-fold increase, p=0.026, Figure 51), but not in the first set of 
volunteers vaccinated with concurrent vaccines. Further, at 9 days post-
inoculation, LAIV Spn- showed an induction of IL-10, similarly demonstrated at 
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Figure 50. LAIV induces anti-inflammatory cytokines IL-10 and HGF in the nasopharynx of 
non-colonised volunteers. Levels of (A) IL-10 and (B) HGF were measured in nasal lining of 
volunteers vaccinated with LAIV and not colonised by Spn (LAIV Spn-, n=18-19) and compared 
at each timepoint to baseline (day -4) by Wilcoxon test with *p≤0.05 and **p<0.01. Medians and 
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Figure 51. Non-colonised volunteers show increased levels of IL-10 in the nose. Levels of 
IL-10 was measured in nasal lining of volunteers in the control group that cleared Spn in the 
nasopharynx (TIV Spn-, n=18-19) and compared at each timepoint to baseline (day -4) by 
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5.4 Discussion 
Here, we assessed cytokine responses elicited by Spn and/or LAIV in the 
human nasal mucosa by collecting nasal lining fluid (nasosorption, NS) from 
volunteers from 2 consecutives randomised controlled clinical trials and 
measured cytokine levels with 30-plex human cytokine panel. Our results have 
demonstrated that the control group, vaccinated with TIV and not colonised by 
Spn, was associated with less general inflammation. The detectable levels of 
inflammatory cytokines in this group corroborate the view of Spn as a commensal 
bacterium that can asymptomatically be present in the nose of healthy adults 336.  
Conversely, the attenuated influenza viruses contained in the LAIV elicited 
induction of pro-inflammatory cytokines, as well as cytokines that regulate 
adaptive immunity and cell growth. However, we observed divergent cytokine 
profiles promoted by antecedent LAIV vaccination in non-colonised and Spn 
colonised, which imply that differences in the host responses to Spn after primary 
influenza infection may affect susceptibility to Spn colonisation. As described in 
wild-type influenza virus and secondary Spn co-infection 271, antecedent LAIV 
vaccination induces an exacerbated immune response that is regulated by a loop 
of positive feedback between immune cells and cytokines. In our results this 
response was characterised mainly by increases in IL-6, IFN-, IP-10, MIP-1, 
MIP-1β and IL-17A in the LAIV/Spn+ group.  
The cytokine IL-6 is considered one of the major physiological mediators 
of acute infection and plays an important role on acquired immune response by 
stimulation of antibody production and of effector T-cell development in vitro and 
in vivo. In mice colonised with Spn, antecedent LAIV-induced IL-6 is shown to be 
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in humans. Additionally, LAIV in Spn colonised induced an increase in IL-17A, a 
cytokine observed in murine models following colonisation and critical for defence 
against bacterial infections, especially Spn 327,333,337. IL-17A is known to induce 
neutrophil recruitment and enhance macrophage capacity to kill Spn in vitro 287. 
The increased IL-17A levels observed in Spn colonised volunteers suggest that 
proliferation of neutrophils may occur in the nasal mucosa after bacterial 
challenge, in order to facilitate control and clearance of growing Spn colonisation. 
On the other hand, although LAIV induced a high pro-inflammatory profile 
in Spn colonised, vaccination reduced specific responses to Spn in humans, 
mainly confined in the chemoattractant cytokines MCP-1, RANTES, MIG, TNF-
, IL-1β and IL-10. In mice models it has been shown that MIG and TNF- 
possess anti-viral activities 188,199,338,339, whereas IL-1β is known for mediate Spn 
clearance 295.  
In addition, LAIV-induced anti-inflammatory IL-10 was reduced by Spn 
colonisation, cytokine that is a central factor for regulating immune responses to 
virus and bacteria 340,129. Here we showed that the attenuated influenza viruses 
contained in the LAIV do not show similar effect to murine models of antecedent 
wild-type influenza and Spn co-infection that have associated impact on the nasal 
epithelium with induction of IL-10 127,341. 
In this study we addressed important questions about how immune 
responses are elicited by LAIV as well as how the attenuated influenza viruses 
contained in the LAIV can alter Spn control in the host. By using for the first time 
2 double human infection challenge model with LAIV and Spn, we revealed that 
Spn colonisation caused minimal alteration in the nasal cytokine milieu, whereas 
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colonised. Our findings are in agreement with studies shown that antecedent 
LAIV increases susceptibility to Spn acquisition and promotes bacterial growth 
284. Secondary Spn infection following wild-type viral respiratory tract infection has 
a large burden of disease worldwide, therefore it is essential to understand how 
LAIV can affect cytokine immune responses that, in turn, lead to increased 
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6.1 Introduction 
Each year, 5–15% of the world's population will suffer from an influenza 
infection, with up to 5 million cases of severe disease and 5 hundred thousand 
deaths 342. Influenza viruses have the ability to mutate 343 and hence escape 
immune defence mechanisms of the host 344, which require annual vaccine 
updates. As described before, the current available vaccines are the TIV and 
LAIV.  
The different vaccination routes of TIV and LAIV trigger distinct immune 
mechanisms and pathways of protection. TIV leads to host protection by inducing 
neutralising antibodies to strain-specific glycoproteins HA and NA 345. LAIV is a 
cold-adapted vaccine that replicates only in the nasopharynx - mimicking a 
natural influenza infection 346. The nasal replication of the attenuated influenza 
viruses leads to recognition of its pathogen-associated molecular patterns 
(PAMPs) by host pattern recognition receptors (PRRs), which initiates a cascade 
of cellular immune responses 344.  
In mice, LAIV vaccination increases the frequency of CD4+ and CD8+ T-
cells in the lung and cytokine production upon influenza re-stimulation compared 
to the inactivated virus vaccination or no vaccine administration 186,188,347,348. 
Moreover, LAIV seeds the murine lung with both CD4+ and virus-specific CD8+ 
TRM T-cells. TRM have been shown to provide long-term cross-strain protection 
to influenza 347. In humans, the immune responses elicited by LAIV have been 
found to provide broader clinical protection in children compared to the 
inactivated influenza vaccines 349. However, the detailed immunological 
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Each year influenza vaccines are formulated according to circulating 
strains, but their effectiveness varies as influenza replication often results in 
antigenic drift and shift, changing the viral genome 350. Estimates from the World 
Health Organisation (WHO) suggest that influenza vaccines effectiveness rarely 
exceeds 60% and has fallen below 30% in some years 351,352. Due to poor 
effectiveness among 2 to 17 year-olds, during previous seasons, the CDC 
Advisory Committee on Immunisation Practices (ACIP) suggested the exclusion 
of LAIV from US national childhood influenza immunisation programme during 
2016-2017 and 2017-2018 season 353, whereas it expressed no preference for 
the LAIV vaccine over the inactivated one for the 2018-2019 influenza season. 
Many underlying causes for this variation have been suggested, including poor 
matching with circulating strains 354, differential ability of some LAIV to induce 
immunity, in particular against H1N1 strains, and interactions with the existing 
microbiome during LAIV replication in the nose 355. 
Despite several reports about the microbiota and its impact on vaccination 
responses 356–359 - including responses to influenza vaccine 358,360 - it is still 
unclear how the microbiome effects LAIV immunogenicity in humans 277. In 
murine models, Spn colonisation altered the anti-viral B-cell responses during co-
infection with wild-type influenza virus, potentially compromising long-term 
antiviral antibody-mediated immunity 277. As colonisation of the nasopharynx with 
Spn is very common during childhood, with 50% of infants in resource-rich 
settings and up to 90% in low and middle income countries colonised at any time 
361, it is essential to continue the investigation on how Spn could affect immune 
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Here, we showed that in humans, concurrent LAIV elicits immune 
responses primarily at mucosal sites- both nose and lung. Interestingly, pre-
existing nasal Spn colonisation impacted on LAIV immunogenicity, dampening 
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6.2 Methods 
 
6.2.1 Volunteer recruitment, vaccination and inoculation 
 
170 healthy adult volunteers were recruited to the Concurrent study 
(Section 2.2). In the Concurrent study, subjects were inoculated with Spn using 
EHPC and 3 days later, vaccinated with either LAIV (n=80) or TIV as control 
(n=90) (Section 2.5.4 and 2.6.4). 
To investigate the immune responses to influenza vaccination, samples of 
NW and serum were collected at baseline and 24 days after vaccination. For 
comparisons within the lung datasets, BAL fluid and lung lymphocytes were 
collected at 1 timepoint, as well as from an unvaccinated subset of volunteers 
(Spn-, n=10 and Spn+, n=10) which were used as a control since each volunteer 
was only able to provide a single time point sample. 
 
6.2.2 Nasal wash, BAL and serum collection and processing 
 
NW was collected by washing volunteers’ nostrils with saline (Section 
2.5.5) while BAL was collected by washing off the lungs with saline (Section 
2.5.9). In addition, serum was also collected (Section 2.5.8). NW and serum 
samples were stored in a -80oC freezer for future analysis (Section 2.6.5), 
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6.2.3 Intracellular cytokine staining of BAL cells 
 
As described in Section 2.6.8.2, non-adherent BAL cells were counted and 
stimulated with TIV or left unstimulated as negative control, and incubated. Cells 
were washed and stained with extracellular markers CD3, TCR-, CD4, CD8, 
CD69, CD25, CD103 and CD49a and intracellular markers FOXP3, IFN-, TNF-
α, IL-10 and IL-17A for analysis in a flow cytometer. 
 
6.2.4 Enzyme-linked immunosorbent assay (ELISA) 
 
ELISA was used to quantify levels of IgG and IgA antibodies to influenza 
in the serum, NW and BAL supernatant of volunteers vaccinated with TIV or LAIV 
as described in Section 2.6.9.5. The average blank corrected value was 
calculated for each sample and the data analysed using Omega Analysis. 
 
6.2.5 Statistical analysis 
The levels of antibodies were analysed by comparing baseline and 24 
days after vaccination (D24) by Wilcoxon test. As described in Section 2.7, the 
number of positive cells were compared between mock and flu-stimulated within 
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6.3 Results 
To assess and compare the immune responses elicited by influenza in 
volunteers inoculated with Spn and vaccinated with concurrent LAIV, we 
collected a series of samples. Mucosal samples, such as NW and BAL, as well 
as serum samples, were collected from the groups TIV Spn- (n=21), TIV Spn+ 
(n=19), LAIV Spn- (n=37) and LAIV Spn+ (n=43). For the assessment of lung 
immune responses, we included a non-vaccinated cohort (Spn-, n=10 and Spn+, 
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Concurrent LAIV increases the frequency of influenza-specific 
TNF- and IFN-γ producing CD4+ and TRM CD4+ T-cells in the 
lung 
 
Data from animal models suggest that concurrent LAIV, but not TIV, elicits 
protective cellular responses in the lung 324,362. To assess if influenza vaccination 
induced cellular responses in humans, BAL cells were stimulated with influenza 
antigens. T-cell subsets (CD4+, CD8+ and TCR-+) were immunophenotyped 
and the frequency of positive IFN-, IL-17A and TNF--producing, influenza-
specific T-cells measured. Frequencies of total CD4+, CD8+ and TCR-+ T-cells 
were not affected by vaccination status (Figure 52).  
Furthermore, we investigated the presence of TRM T-cell responses to 
influenza, using the extracellular markers CD69, CD103 and CD49a. As over 1/3 
of CD4+ CD69+ cells, commonly defined as TRM 294 did not express the additional 
resident memory markers CD103 and CD49a, we defined TRM only as CD69+. 









Figure 52. Concurrent LAIV and TIV do not affect frequencies of total CD4+, CD8+ and 
TCRδ+ T-cell subsets in the lung. Subset frequencies among viable T-cells were measured 
after an overnight incubation of isolated BAL cells. Bars depict the median proportion of T-cell 
subsets among total T-cells for TIV Spn- (n=9), TIV Spn+ (n=11), LAIV Spn- (n=11) and LAIV 
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CD4+ TNF- production upon influenza stimulation was observed in both TIV 
and LAIV recipients regardless of colonisation status, but not in unvaccinated 
individuals (Figure 61A and 61B). However, levels of influenza-specific TNF- 
were significantly increased in LAIV Spn- when compared to the unvaccinated 
(mean 2.6-fold increase, p=0.015, Figure 61B).  
Following stimulation with influenza antigens, CD4+ TRM T-cells produced 
TNF- in all vaccinated groups but not in the unvaccinated group (Figure 61C). 
The induction of TNF- producing CD4+ TRM following stimulation did not 
significantly differ between TIV and LAIV, but was more pronounced in the LAIV-
vaccinated, in both Spn colonised and non-colonised individuals (LAIV Spn+: 
mean 6.5-fold change to unvaccinated, p=0.004; LAIV Spn-: mean 7.7-fold 
change to unvaccinated, p=0.024) compared to the unvaccinated group (Figure 
61D). 
We also assessed IFN- production by total CD4+ and TRM CD4+ T-cells 
residing in the human lung. IFN- production by total CD4+ T-cells was observed 
in all groups upon stimulation, including the unvaccinated group (Figure 61E). 
The levels of IFN- producing CD4+ T-cells were not different when comparing 
vaccinated and unvaccinated groups. However, the induction of IFN- producing 
CD4+ TRM T-cells was greater in the LAIV-vaccinated volunteers (Figure 61F). 
In contrast to total CD4+ T-cells, stimulation of TRMs of unvaccinated individuals 
did not elicit an IFN- response (Figure 61F).  
Furthermore, the proportion of IL-17A producing CD4+ T-cells or CD4+ TRM 
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Figure 53. Concurrent LAIV increases frequency of influenza-specific TNF- and IFN--producing 
CD4+ and TRM CD4+ T-cells in the lung. Frequencies of cytokine-producing CD4+ and TRM CD4+ T-cells 
were measured in human BAL samples with and without (mock) in vitro influenza antigen stimulation. 
Volunteers were divided by vaccine and colonisation status in TIV Spn- (n=6), TIV Spn+ (n=8), LAIV Spn- 
(n=10), LAIV Spn+ (n=9), unvaccinated (Spn-, n=3 and Spn+, n=5) group. (A) Production of TNF-α by total 
CD4+ T-cells in each group [paired unstimulated (mock) and stimulated condition (flu)]. (B) influenza-specific 
production of TNF-α by total CD4+ T-cells (Difference between influenza-stimulated and unstimulated) in 
each group. (C) Production of TNF-α by CD4+ CD69+ T-cells in each group. (D) Production of influenza-
specific TNF-α by CD4+ CD69+ T-cells in each group. (E) Production of IFN- by total CD4+ T-cells and (F) 
CD4+ CD69+ T-cells in each group. Each individual dot represents a single volunteer and the conditions from 
one individual are connected. Medians with IQR are depicted for influenza-specific responses, *p<0.05, 
**p<0.01 by Wilcoxon test for comparisons within the same group and by Mann-Whitney test for between-
group comparisons. 
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Figure 54. Concurrent LAIV and TIV do not increase the frequency of influenza-specific, IL-
17A-producing T-cells in the lung. The frequency of cytokine-producing cells was measured by 
intracellular staining flow cytometry analysis after stimulation with influenza antigens or 
unstimulated for TIV Spn- (n=8), TIV Spn+ (n=6), LAIV Spn- (n=10), LAIV Spn+ (n=9), 
unvaccinated Spn- (n=3), unvaccinated Spn+ (n=5). IL-17A production in (A) total CD4+ T-cells, 
(B) CD4+ CD69+ T-cells, (C) total CD8+ T-cells and (D) CD8+ CD69+ T-cells. Each individual dot 
represents a single volunteer and the conditions from one individual are connected. **p<0.01. 
The unstimulated and influenza antigen-stimulated responses were compared within each group 
by Wilcoxon test. Influenza-specific responses (influenza-stimulated - unstimulated) were 
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Concurrent LAIV increases the frequency of TNF- producing 
influenza-specific CD8+ and TRM CD8+ T-cells in the lungs 
 
Re-stimulation induced increased production of TNF-α producing CD8+ T-
cells in LAIV but not TIV or unvaccinated group. LAIV-vaccinated non-colonised 
had a mean 2.3-fold increase of TNF-α producing CD8+T-cells post stimulation 
compared to the non-stimulated condition (p=0.030), whereas the same type of 
cellular response was less pronounced in the Spn colonised volunteers (mean 
1.9-fold increase, p=0.007, Figure 63A). Similarly, TNF-α production by TRM 
CD8+ cells was only observed in the LAIV-vaccinated group, increased by median 
3.1- (p=0.006) and 2.1- (p=0.004) fold change in non-colonised and colonised 
subjects, respectively (Figure 63B). 
In contrast to CD4+ responses, production of IFN- by stimulated CD8+ T-cells 
was only induced in the LAIV-vaccinated colonised by Spn (mean 1.6-fold change 
with IQR: 1.5x-2.7x, p=0.007, Figure 63C). TIV and control group had no 
significant increase in the proportion of IFN- producing CD8+ T-cell post 
stimulation with influenza antigens. In addition, IFN- production by lung TRM 
CD8+ T-cells not significantly altered post stimulation in any of the groups (Figure 
63D).  
Stimulation did not elicit production of IL-17A producing CD8+ T-cells, except 
for IL-17A production by TRM CD8+ T-cells in the Spn colonised group (mean 
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Figure 55. Concurrent LAIV increases frequency of TNF- producing influenza-specific 
CD8+ and TRM CD8+ T-cells in the lungs. Frequencies of cytokine-producing CD8+ T-cells were 
measured in human BAL samples by intracellular staining flow cytometry analysis following 
stimulation with influenza antigens or non-stimulation (mock) in each group. Volunteers were 
divided by vaccine and colonisation status in TIV Spn- (n=6), TIV Spn+ (n=8), LAIV Spn- (n=10), 
LAIV Spn+ (n=9) and unvaccinated (Spn-, n=3 and Spn+, n=5) group. Production of TNF-α by (A) 
total CD8+ T-cells and (B) TRM CD8+ T-cells in each group (paired unstimulated [mock] and 
stimulated condition [Flu]). Production of IFN- production by (C) total CD8+ T-cells and (D) TRM 
CD8+ T-cells in each group. Each individual dot represents a single volunteer and the conditions 
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Figure 56 Concurrent LAIV and TIV do not increase the frequency of influenza-specific, IL-
17A-producing T-cells in the lung. The frequency of cytokine-producing cells was measured by 
intracellular staining flow cytometry analysis after stimulation with influenza antigens or 
unstimulated for TIV Spn- (n=8), TIV Spn+ (n=6), LAIV Spn- (n=10), LAIV Spn+ (n=9), 
unvaccinated Spn- (n=3), unvaccinated Spn+ (n=5). IL-17A production in (A) total CD4+ T-cells, 
(B) CD4+ CD69+ T-cells, (C) total CD8+ T-cells and (D) CD8+ CD69+ T-cells. Each individual dot 
represents a single volunteer and the conditions from one individual are connected. **p<0.01. 
The unstimulated and influenza antigen-stimulated responses were compared within each group 
by Wilcoxon test. Influenza-specific responses (influenza-stimulated - unstimulated) were 
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Concurrent LAIV increases frequency of influenza-responding 
IFN- producing TCR-δ+ in the lungs of non-colonised 
individuals 
 
TCR-δ+ cells, a subset of specialised innate-like T-cells that can exert 
effector functions immediately upon activation, play an important role in 
pulmonary infection 363,364. Therefore, we assessed whether TCR-δ+ T-cell 
responses to influenza antigens were induced following vaccination. No 
significant increase in TNF-α producing TCR-δ+ was observed after stimulation 
in any of the groups (Figure 65A). However, the proportion of IFN- producing 
TCR-δ+ was significantly greater in LAIV vaccinated non-colonised (median 2.9- 
fold increase upon stimulation compared to the unstimulated condition, (p=0.002, 
Figure 65B). None of the other vaccinated or unvaccinated groups showed a 
significant induction of IFN- production. Similar to the other T-cell subsets, IL-
17A producing TCR-δ+ cells did not significantly increase after stimulation with 









Figure 57. Concurrent LAIV increases frequency of IFN- producing influenza-specific 
TCR-δ+ in the lungs of Spn non-colonised individuals. Frequency of cytokine-producing 
TCR-δ+ T-cells was measured in human BAL samples by intracellular staining flow cytometry 
analysis after in vitro stimulation with influenza antigens or non-stimulation (mock). Volunteers 
were divided by vaccine and colonisation status in TIV Spn- (n=6), TIV Spn+ (n=8), LAIV Spn- 
(n=10), LAIV Spn+ (n=9) and unvaccinated (Spn-, n=3 and Spn+, n=5) group. Production of (Α) 
TNF-α, (Β) IFN- and (C) IL-17A by lung TCR-δ+ T-cells. Individual dot represents a single 
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Concurrent LAIV increases frequency of CD4+ regulatory T-cells 
in the lung of non-colonised individuals 
 
A balanced immune response in the lung has been demonstrated to be 
important in preventing pneumonia 132. To investigate whether concurrent LAIV 
could alter frequency of T-regs in the lung, we measured the frequency of CD25hi 
FOXP3+ T-regs among CD4+ T-cells using intracellular staining. Increased levels 
of CD4+ T-regs were only significantly different in BAL samples of LAIV non-
colonised when compared to unvaccinated individuals (mean 1.5-fold increase, 
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Figure 58. Concurrent LAIV increases frequency of CD4+ regulatory T-cells in the lung of 
Spn non-colonised individuals. Frequency of unstimulated CD4+ T-regs (CD3+ CD4+ CD25+ 
FOXP3+) was measured by flow cytometry in human BAL samples from TIV Spn- (n=6), TIV Spn- 
(n=8), LAIV Spn- (n=10), LAIV Spn+ (n=9) and unvaccinated (Spn-, n=3 and Spn+, n=5). Each 
individual dot represents a single volunteer and geometric means with 95% CI are shown. *p<0.05 
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TIV but not concurrent LAIV vaccination increases levels of IgG 
to influenza in serum 
 
In addition to cellular responses, we sought to assess humoral responses 
elicited by TIV and concurrent LAIV vaccination both systemically and at the 
mucosal sites (nasal and lung). In serum samples, IgG levels against influenza 
antigens were measured at baseline (prior to bacterial challenge and influenza 
immunisation) and at 24 days post vaccination. TIV induced a median 5.9-fold 
increase (p<0.0001) of influenza-specific IgG, while LAIV intranasal 
administration did not confer increase of sera IgG levels (Figure 59A). Prior 
colonisation of the nasopharynx with Spn did not alter influenza-specific IgG 
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Figure 59. TIV but not concurrent LAIV vaccination increases levels of IgG to influenza in 
serum. (A) Geometric mean of IgG levels to influenza, measured by ELISA, in serum of LAIV 
(n=36) and TIV (n=36) vaccinated subjects at baseline (8 days pre-vaccination) and D24 (24 days 
post-vaccination). (B) Fold change (D24/Baseline) of paired IgG titres to influenza in serum 
following TIV or LAIV vaccination. TIV Spn- (n=20), TIV Spn+ (n=16), LAIV Spn- (n=18); LAIV 
Spn+ (n=18). Medians with IQR are shown. ****p<0.0001 by Wilcoxon test for comparisons within 
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IgG but not IgA is induced by influenza vaccines in the lung, with 
concurrent LAIV mediated-responses being impaired by Spn 
colonisation 
 
Humoral responses in the lung following TIV or concurrent LAIV vaccination 
were assessed in BAL samples collected between 26 to 46 days post influenza 
vaccination. Due to the single timepoint sampling of the lung, 20 unvaccinated 
subjects (10 Spn-colonised and 10 non-colonised) were used as a control group.  
Levels of IgA to influenza in the lung did not differ between TIV, LAIV and 
control groups (Figure 60A). In terms of IgG levels, TIV was associated with a 
high IgG response (median 5.8-fold increase compared to control, p<0.0001), 
whereas LAIV conferred a modest IgG induction (median 1.6-fold change 
compared to control, p=0.028, Figure 60B). TIV elicited influenza-specific IgG 
levels were 3.7x greater than LAIV-induced responses in the pulmonary mucosa 
(Figure 60B).  
IgA levels were not significantly increased in the lung by vaccination and were 
not affected by Spn colonisation (Figure 61C). Spn colonisation affected IgG titres 
in the LAIV vaccinated group, but not in the TIV group. IgG to influenza was higher 
in LAIV Spn- compared to colonised (LAIV Spn+, median 1.35-fold increase, 
p=0.010), however the colonised group was not different from the control group 
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Spn colonisation impairs nasal IgA induction following LAIV but 
does not alter responses to TIV 
 
To assess antibody responses at the nasal mucosa, we measured influenza-
specific IgA and IgG levels in NW samples at baseline and 24 days following 
influenza immunisation. TIV induced a median 2.2- and a 5.2-fold increase in 
influenza virus-specific IgA and IgG levels, respectively, 24 days post-vaccination 
(Figure 61A and 61B). On the other hand, LAIV-induced IgG antibody responses 
were weakened compared to those induced by TIV. LAIV nasal administration 
resulted to increase of IgA titres to influenza (median 1.3-fold increase, IQR: 0.7x-
2.1x, Figure 61A), whereas the induction of IgG levels (median 1.4-fold increase) 
was moderated if seen alongside the corresponding induction resulted by TIV. 
(Figure 61B).  
Reduced LAIV-mediated immunogenicity, as observed for lung cellular 
responses, was also observed for humoral responses at the nasal mucosa of Spn 
colonised volunteers. Concurrent colonisation of the nasopharynx with Spn 
affected IgA titres, but not IgG, in the LAIV-vaccinated (Figure 61C and 61D). At 
day 24 post-vaccination, LAIV-vaccinated non-colonised had significantly greater 
levels of IgA to influenza circulating in the nasal lumen, compared to the colonised 
group (LAIV Spn- median=1.69, IQR: 0.98-2.65 vs LAIV Spn+ median=1.24, IQR: 
0.66-1.81, p=0.020, Figure 60C). Concurrent Spn colonisation did not alter 
antibody responses to influenza in the TIV-vaccinated individuals (Figure 61C 
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Figure 60. IgG but not IgA is induced by influenza vaccines in the lung, with concurrent 
LAIV responses being reduced during Spn colonisation. (A)-(B) Geometric mean of IgA and 
IgG titres to influenza for TIV (n=20), LAIV (n=19) vaccinated subjects and unvaccinated (n=20) 
was measured by ELISA in BAL fluid. (C)-(D) Geometric mean of IgA and IgG titres grouped 
based on vaccination and colonisation status, as TIV Spn- (n=9), TIV Spn+ (n=11), LAIV Spn- 
(n=11), LAIV Spn+ (n=8), unvaccinated (n=20). *p<0.05, **p<0.01, ****p<0.0001 by Wilcoxon test 
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Figure 61. Spn colonisation impairs nasal IgA induction following concurrent LAIV but 
does not alter responses to TIV. (A) Geometric mean of IgA and (B) IgG titres to influenza 
measured by ELISA in NW of TIV (n=40) and LAIV (n=80) vaccinated subjects at baseline (8 days 
pre-vaccination) and D24 (24 days post-vaccination). (C) Fold change (D24/Baseline) of paired 
IgA and (D) IgG titres to influenza in NW following vaccination with TIV Spn- (n=21), TIV Spn+ 
(n=19), LAIV Spn- (n=37), LAIV Spn+ (n=43). Medians with IQR are shown. *p<0.05, ***p<0.001, 
****p<0.0001 by Wilcoxon test for comparisons within the same group and by Mann-Whitney test 
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6.4 Discussion 
As we demonstrated here, the 2 available influenza vaccines (TIV and 
LAIV), induce immune responses in the host via the innate and adaptive 
pathways 365. However, there is a lack of detailed understanding of the 
immunological mechanisms induced by these vaccines and how this induction 
affects Spn colonisation. 
In this study, we sought to investigate the cellular and humoral immune 
responses elicited by TIV and concurrent LAIV, focusing on respiratory tract 
mucosal sites, in addition to assessing whether colonisation of the nasopharynx 
with Spn influences vaccine immunogenicity. The results indicate that TIV and 
LAIV confer differential immunity to adults. TIV mainly induces high levels of 
influenza-specific antibodies in the serum and mucosal sites, while LAIV 
combines less pronounced mucosal humoral responses with enhanced cellular 
immunity in the lung. Importantly, LAIV immunogenicity is diminished by the nasal 
presence of Spn and this important confounder should be considered when 
assessing LAIV efficacy. 
TIV, as well as other inactivated influenza vaccines 366,367, is known to 
induce higher titres of serum hemagglutination-inhibiting IgG and IgA antibodies 
when compared to LAIV 366–368. On the other hand, LAIV was demonstrated to 
induce higher levels of nasal mucosa IgA to influenza when compared to TIV 14, 
which mainly elicits IgG antibodies in the nasal mucosa 222.  
Mucosal lymphocytes are considered the dominant source of IgA 29 and 
IgG 369 in the nose, with IgG also originated by transudation or diffusion from 
plasma 369. It is important to be mentioned that IgA is the most abundant 
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express signals that play immunomodulatory role in these mucosal surfaces 29. 
In the nose, IgA performs critical functions such as neutralisation of antigens 370, 
modulation of B-cell responses 188,270,277. While IgA is the predominant 
immunoglobulin found in the upper airways, IgG titers increase progressively in 
the lower respiratory tract - being the predominant immunoglobulin in the lung 29 
– and IgG deficiency is associated with susceptibility to pneumonia and 
respiratory tract infections 29. 
In agreement with previous studies213, TIV vaccination induced high 
systemic and mucosal antibody responses, whereas LAIV elicited both mucosal 
(mainly IgA) influenza virus-specific antibodies and cell-mediated immune 
responses. Interestingly, pre-existing Spn colonisation of the nasopharynx 
reduced these LAIV-mediated immune responses but left TIV-induced responses 
unaltered which is corroborated by studies that show that Spn can impact LAIV-
induced responses in the human nasal microbiome as it develops cellular and 
adaptive immunity to the bacteria in the site of the attenuated influenza viruses 
replication 49,62. 
We also showed that – in contrary to published results of immune 
responses 10 days 371 and 6 weeks after vaccination in mice 372– the numbers of 
CD3+, CD4+ and CD8+ T-cells in the lung were similar between TIV and LAIV 
vaccinated subjects.  
In the lungs, LAIV prevailed over TIV on cellular induced responses. LAIV 
nasal administration led to increased lung levels of TNF-α and IFN- producing 
CD4+ T-cells, including TRMs, as well TNF-α producing CD8+ T-cells, upon in 
vitro stimulation. Interestingly, we observed that influenza-specific CD4+ T-cell 
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the time of vaccination. Similarly, there was a higher proportion of IFN- producing 
TCR-+ T-cells in the non-colonised LAIV recipients. Moreover, LAIV was 
associated with increased frequencies of lung regulatory T-cells only in the 
absence of nasal Spn colonisation. On the other hand, LAIV-vaccinated 
individuals who were colonised by Spn elicited IL-17A-producing CD8+ T-cells 
which is consistent with findings in previous studies with humans 287 and mice in 
which this cytokine was essential for bacterial control and clearance during wild-
type influenza and Spn co-infection 256. 
Humoral responses were highly induced by TIV, whereas LAIV conferred 
an overall modest antibody induction. Systemically, TIV elicited influenza virus-
specific IgG responses, which were not observed in the LAIV vaccinated arm. In 
the nose, TIV conferred predominantly IgG induction, while LAIV was mainly 
associated with high levels of IgA. Colonisation of the nasopharynx with Spn at 
the time of LAIV administration impaired the induction of mucosal IgA to influenza 
in the nose, but not in the lung. 
LAIV in adults, unlike children, does not confer superior protection 
compared to TIV 14. This is probably related to the life-long accumulation of 
influenza immunity through natural exposure and previous vaccinations, which 
can prevent the nasal replication of the attenuated virus and shorten the viral 
replication cycle 373. Consequently, LAIV may elicit less potent responses in 
adults compared to children, thus any extrapolation from findings in adults to 
children, the target population for this vaccine, must be done with caution.  
Our finding that concurrent Spn colonisation could inhibit LAIV-induced 
immune responses is a variable that should be taken into account when 
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This finding would potentially explain why one study in Senegal showed no 
efficacy of vaccination with LAIV 376, as Spn colonisation rates are higher in low-
income countries (up to 93% of children colonised by Spn) 377. The impaired 
LAIV-induced immunity during established Spn colonisation was associated with 
a lack of a pro-inflammatory response in the nasal lumen following LAIV 
vaccination. A possible explanation for this is that Spn colonisation affects local 
immune and epithelial cell responses upon LAIV vaccination, which could 
diminish immune cells infiltration and antigen presenting cells (APC) activation, 
impacting on the downstream memory responses 282,378. Alternatively, it is 
possible that Spn colonisation interferes with the viral replication cycle 256,379. 
Ideally, an effective and broadly protective influenza vaccine should 
induce both humoral and cellular immunity. Whereas antibody responses to 
influenza show some degree of strain cross-reactivity 380,381 they are insufficient 
to provide heterosubtypic, cross-strain influenza protection 382,383 Recent data 
from natural history cohort studies have focused on the potential of T-cells as key 
players in mediating heterosubtypic immunity in humans 124,384. We observed that 
even in the absence of vaccination, healthy adults showed CD4+ T-cell responses 
to influenza stimulation, which likely reflects their lifelong exposure to influenza 
viruses. The use of purified influenza antigens included adjuvant, to measure 
cellular responses, would possibly lead to greater T-cells responses. Our results 
demonstrated that LAIV induced influenza-specific cytokine-producing CD8+ and 
CD4+ T-cells, including TRM in the lung. As part of T-cell immune response to 
influenza, recent studies have elucidated the importance of TRM in protection of 
mucosal barrier tissues against pathogen challenge by producing chemokines for 
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protection to influenza infection when compared with circulating T-cells386. By 
seeding the lungs with these cells, it is possible to establish long-term 
heterosubtypic protection to influenza 387,388.  
We have also demonstrated that, in volunteers not colonised by Spn, LAIV 
increased levels of T-regs in the lung compared to unvaccinated individuals. 
CD4+ T-regs contribute to homeostasis of the immune system, controlling 
infection by respiratory viruses and avoiding tissue damage92 and secondary 
bacterial infection 389. As a result of recurrent exposure to virus and bacteria, 
CD4+ T-regs increase in frequency with age 390. For this reason, our findings in 
adults might underestimate the effect of LAIV on frequency of T-regs in the lung 
of children. 
In conclusion, using a controlled human infection model at a known time 
relative to vaccination, this study was able to highlight differences in 
immunogenicity between LAIV and TIV at relevant mucosal sites. Moreover, we 
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7.1 Introduction  
 
The investigation of host immune responses to pathogens during 
attenuated influenza virus (LAIV) and Spn co-infection in the nasopharynx is 
essential for deeper understanding of interactions between host, attenuated virus 
and bacteria. These insights clarify effects of co-infection on viral and bacterial 
clearance, acquisition, replication, transmission as well as efficacy of the 
attenuated influenza vaccine to ultimately to promote better immunisation 
approaches to the population. In humans, wild-type influenza virus can 
predispose to secondary Spn colonisation and, likewise, the bacteria can induce 
viral shedding 391 which, in turn, deregulates inflammatory responses and leads 
to loss of control of Spn density 392. Interestingly, in murine models of co-infection, 
sialic acid cleaved from host’s epithelium by the influenza virus is consumed by 
Spn promoting growth 75 which indicates the need for further research in humans 
in order to corroborate the hypothesis. 
In this study, LAIV-induced influenza-specific immune responses were 
compared to TIV using nasal wash, nasosorption, nasal cells, BAL and serum of 
healthy adult volunteers. In addition, by inoculating individuals with live Spn 
(EHPC), we assessed how responses to LAIV affect Spn colonisation as well as 
how the bacteria affects vaccine immunogenicity. The primary underlying 
mechanisms of cell recruitment, cytokine and antibody production were also 
investigated. Altogether, this thesis is part of the largest conducted vaccine 
testing studies using a controlled human infection model as well as the first 
controlled challenge studies in humans using two live pathogens to directly 
assess the impact of a vaccine on microbiota. In short, we observed that different 
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vaccinated volunteers who became colonised by Spn when compared to non-
colonised.  
7.2 Summary and discussion of findings 
 
To gather knowledge about LAIV and how the attenuated influenza virus 
vaccination affects Spn colonisation is essential for accurate assessment of 
vaccine immunogenicity in humans and its effect on the nasopharyngeal 
microbiota and host immunity. This work was based on previous studies with wild-
type influenza virus and Spn co-infection that show it to be associated with 
increased bacterial nasal load in mice 275,281,393 and humans 256,266. Importantly, 
LAIV administration has also been correlated with increase in Spn density in mice 
75,76 and humans 318,394, however the underlying mechanisms were still not 
elucidated. 
Here, we showed that LAIV in healthy adults induces inflammatory 
responses in the nasopharynx, including cytokines that regulate adaptive 
immunity as previously described in other studies 395. Importantly, our results 
confirm that the attenuated virus elicits many of the same immune responses as 
the wild-type influenza, such as induction of cytokines IL-6 262 and IL-1β 396. 
In addition, in the lung LAIV alone still induced moderate antibody levels 
against influenza after 30 days post-vaccination. Moreover, T-cell responses 
were increased with higher percentages of CD4+ T-cells producing IFN- as well 
as CD4+ and CD8+ T-cells producing TNF-, two cytokines also induced in the 
murine lung by LAIV administration 372. Additionally, TRM T-cells, which persist 
in the lung for long periods after infection 388 - were shown to have an important 
role for lung cytokine response against the attenuated influenza virus, similar to 
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Models of co-infection with the attenuated influenza virus and Spn show 
induction of adaptive immune responses in the nose and lung to achieve viral and 
bacterial clearance to be necessary during co-infection 188. In this thesis, we 
showed that LAIV induces a state of inflammation in the nasopharynx 
independent of Spn that predisposes the host to colonisation. In addition, is 
possible that vaccination also causes epithelial damage, dysfunction or 
denudation in the colonised nose as indicated by increases in cytokines that 
regulate cell growth and that corroborates results in murine models with wild-type 
influenza and Spn co-infection 193,271,398. Furthermore, we have shown that in the 
lung co-infection of attenuated influenza virus and Spn does not elicit IL-17A-
producing CD8+ T-cells, which opposes previous studies with wild-type influenza 
256,287.  
However, when compared to non-colonised volunteers, our results show 
that some of the host immune responses were affected by LAIV which 
corroborated murine models of wild-type influenza virus and Spn co-infection 
that, likewise, demonstrate impaired induction of anti-inflammatory cytokines 
127,399, of monocyte recruitment 186, of influenza specific antibodies 188 and of 
neutrophils activation 192. Notably, we demonstrated for the first time that LAIV 
vaccination in Spn colonised volunteers impaired activation of T-cells in the 
nasopharynx.  
Additionally, LAIV impaired the induction of chemoattractant to monocytes 
such as MCP-1 400 and RANTES 401,402 in the Spn colonised nasopharynx, 
possibly limiting monocyte recruitment to the nose as observed in our results. 
These results confirm the hypothesis that unbalanced cytokines affect 
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virus similarly to the wild-type virus 403. Furthermore, the impairment of MCP-1 
can also explain decreased induction in levels of IL-1β whereas the impairment 
of RANTES can clarify reduced T-cell activation 404 demonstrated in our results.  
It is important to notice that previous studies have demonstrated that Spn 
colonisation induces cytokines TNF- 122 in the nasopharynx, however our results 
show that LAIV affects Spn-induced TNF-, possibly affecting control of the 
infection. Moreover, here we confirmed that LAIV induces specific antibody 
responses against influenza characterised by IgG and particularly IgA in nasal 
wash 240, however, we showed for the first time that LAIV-induced IgA production 
was reduced in the Spn colonised nasopharynx which adds to the uncontrolled 
bacterial growth 370 by neither neutralising antigens or preventing the attenuated 
influenza virus and Spn adherence to epithelial cells 29 
Importantly, the detected LAIV impact in the lung of colonised volunteers 
corroborate wild-type influenza virus and Spn co-infection animal models in which 
influenza-specific IgG and CD4+ T-cells were impaired when compared to non-
colonised individuals 270. However, our results in adults do not confirm murine 
studies in which CD4+ T-reg are increased in co-infected animals 188. 
In summary, we demonstrated that LAIV induces an inflammatory state in 
the nasopharynx of healthy adults. On one hand, the immune deregulation 
caused by LAIV vaccination in Spn colonised individuals caused substantial 
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7.3 Limitations of LAIV research in humans 
 
Despite its proven success in preventing infectious diseases, the vast 
majority of vaccines used today for human immunisation have been developed 
empirically, at first often with little understanding of the immune mechanisms by 
which they induce protective immunity. This work has uncovered some limitations 
in the assessment of immunogenicity and research of LAIV-induced responses 
which will contribute to more accurate understanding of the vaccine as well as to 
shed a light on the impact of vaccination on other pathogens, specifically Spn. 
Importantly, LAIV vaccination in adults induces different immune 
responses compared to children 14 - the target population for this vaccine - as a 
result of induced neutralising antibodies due to previous exposure to influenza 
virus during their lives. Continuous exposure to influenza virus can prevent the 
nasal replication of the attenuated virus contained in the LAIV 373 as well as elicit 
natural immunity against influenza antigens. Consequently, extrapolation of these 
results to the paediatric population must be done with caution especially 
regarding T-regs, recruitment of monocytes and activation of neutrophils, already 
proven to not be analogous to adults. 
In addition, the relationship between LAIV and Spn colonisation rates 
presented in this thesis uses nasal wash and classical microbiology. Other 
techniques or devices for assessment of colonisation rates such as nasosorption 
405, nasal curettage 406 and bronchoabsorption 407 were not validated and should 
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7.4 Future research directions and questions derived from this 
thesis 
 
Most studies on co-infection of LAIV and Spn have been done in animal 
models. Here we have shown discrepancies in results when comparing LAIV or 
wild-type influenza virus and Spn co-infection results from murine models with 
human models. The extrapolation of immune responses between murine models 
and humans can be problematic since mice doesn't represent the complexity of 
microbiome and immunity of the human host 408. As noted by Ferreira, Jambo 
and Gordon 53, humans are natural hosts of Spn and each individual has been in 
contact and colonised numerous times throughout their life while mice models 
are pathogen-free and only susceptible to the bacteria in laboratorial conditions, 
skewing the results. In addition, chinchillas and ferrets are also used as co-
infection models but likewise present great difficulties to confirm similar results in 
humans 260. 
Moreover, to study co-infection of the attenuated influenza virus and Spn, 
we have used only one Spn serotype 6B isolate, which limits the scope of our 
results. Future studies using other isolates with variable invasive phenotypes 
could answer how generalizable these findings are across serotypes. 
In addition, further studies into mucosal immunology using different 
techniques for sample collection can validate the results found in this thesis and 
enable further discoveries on patient groups who are unable to undergo the 
procedures proposed. Importantly, methods for collection of nasal lavage, nasal 
cells and lung lavage used in this thesis (NW, nasal curettage, nasosorption and 
BAL) can be compared to alternative techniques such as nasosorption with 
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Moreover, serial nasosorption can be performed for assessment of nasal 
cytokines, antibodies and viral load kinetics. For instance, studies of early hours 
kinetics can be done with this technique as well as NW and saliva 409 for further 
understanding mucosal events since many cytokine responses are concentrated 
in the first 48 hours of immunological response. 
Notably, it is critical to continue the assessment of the best sampling 
device and site to measure Spn colonisation and bacterial density. This can be 
done by comparison of sampling and analysis methods, for instance nasosorption 
results against NW, nasal transcriptomics of nasal curettage results against flow 
cytometry as well as bronchoabsorption results against BAL. 
It is important to notice that methodologies such as nasal curettage can 
take into consideration the rate of ciliated respiratory epithelial cells to squamous 
stratified epithelial cells as to assure the results accuracy of cell recruitment to 
the mucosa. 
Continuous development of the EHPC method as well as other multiple 
pathogens challenge models are essential to elucidate the potential for viral 
pandemics, secondary infections and interactions between bacteria, virus and 
human host as well as identification of health indicators and therapies for 
prevention of high morbidity scenarios. Furthermore, studies focused on analysis 
of the 4 specific virus strains contained in the LAIV can validate novel 
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Table 9. Suggestions for future studies, method validation and development of 
challenge models. 
 
Field of research Suggested studies Specific suggestions 
Alternative methods 
for sample collection 
Development of alternative 
sampling methods for different 
patient groups (smokers, elderly, 
asthmatics, children). 
• Bronchial brush. 
• Bronchoabsorption; 
• Serial nasosorption; 
 
Challenge models for 
vaccine testing 
Development of a human nasal 
challenge model with LAIV and 
viral vaccines to measure 
responses to nasal strain-specific 
viruses with more detailed 
mucosal kinetics. 
• Focus on collection of 
serial nasosorption, 
nasal scrape and 
bronchoabsorption; 
• LAIV and novel viral 
vaccines studies; 




Validation of results in this thesis 
using different serotypes of Spn. 
• Serotypes 1, 3, 4, 5, 
6A, 6B, 7F, 9V, 14, 
18C, 19A, 19F, and 
23F. 
Point-of-care assays 
Development of antibody, 
cytokines, viral and bacterial load 
indicators of healthy and 
unhealthy patients. 
 
• Cytokines and 
chemokines; 
• Nasal mucosal 
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• Spn, bacteria and 
microbiome; 
• Viral infections. 
Secondary viral 
infections 
Study of the relationship between 
respiratory and gastrointestinal 
pathogens and human 
microbiome in diseases in which 
virus are the main cause of 
hospitalising exacerbations and 
mortality. In addition, studies on 
the propensity of different viruses 
to alter innate respiratory 
mucosal immunity. 
• Asthma; 
• Chronic obstructive 
pulmonary disease; 
• Cystic fibrosis. 




Validation of novel sampling and 
measurement methods of Spn 
colonisation and density. 
• BAL; 
• Bronchial brushing; 
• Nasal curettage; 
• Nasal curettage 
followed by 
transcriptomics. 
Validation of results 
Validation of this thesis results 
using different sampling 
techniques.  
- Bronchoabsorption; 
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- Nasal curettage 
assessed by 
transcriptomics; 
- Nasal swabs; 
- Nasopharyngeal 
aspirates; 
- Nasosorption for 
measurement of Spn 
density; 
- Nasosorption with 
different synthetic 
absorptive matrix;  
- Other methods of 
nasal lavage; 
- Collection of saliva. 
Viral challenge 
models 
Development of experimental 







LAIV vaccination remains efficient in the long term as it protects children 
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lack preformed virus antibodies 395. Importantly, LAIV vaccination protects the 
host from future virus infections thus preventing a secondary Spn colonisation 274.  
Our finding that Spn colonisation could inhibit LAIV-induced immune 
responses is a variable that should be taken into account when evaluating LAIV 
efficacy, as children display high rates of Spn colonisation 374,375. As colonisation 
rates are higher in low-income countries (up to 93% of children colonised by Spn) 
377, these results could potentially explain one study in Senegal that showed no 
efficacy of vaccination with LAIV 376 , although mismatch of circulating influenza 
virus strains with the vaccine was a limitation to accurate assessment. 
In short, this thesis provides new topics for continuity of human research 
into LAIV and its relationship with the microbiota, which is necessary to further 
elucidate the impacts of mass immunisation with live attenuated virus vaccines 
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